Process for preparation of aminodiaryl ethers and aminodiaryl ether hydrochlorides

By using palladium catalysts in polar aprotic solvents for catalytic hydrogenation reduction and hydrochloric acid treatment, the problems of catalyst contamination and side reactions of aminodiaryl ether compounds were solved, and a high-purity and high-stability hydrochloride salt form was obtained, which is suitable for the industrial production of pharmaceutical formulations.

CN119019324APending Publication Date: 2024-11-26CELLESTIA BIOTECH AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411134795.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-06-21
Filing Date
2019-06-20
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing technologies for preparing amino diaryl ether compounds suffer from catalyst contamination and side reactions, resulting in insufficient compound purity and physical stability, making it difficult to meet pharmaceutical-grade requirements.

Method used

Catalytic hydrogenation reduction was carried out using a palladium catalyst in a polar aprotic solvent or C3-C10 alcohol, followed by conversion of the compound into its hydrochloride salt. The amount of catalyst and reaction conditions were controlled to improve purity and stability.

Benefits of technology

It achieves high purity (99.9%) of amino diaryl ether compounds and high melting point of their hydrochlorides (e.g., 173 °C for 6-(4-(tert-butyl)phenoxy)pyridine-3-amine hydrochloride), improves the physical stability and water solubility of the compounds, and makes them suitable for industrial-scale production of pharmaceutical formulations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019324A_ABST
    Figure CN119019324A_ABST
Patent Text Reader

Abstract

The present invention relates to a process for the preparation of aminodiaryl ethers and aminodiaryl ether hydrochlorides. The present invention relates to a process for the preparation of a compound of formula (I) as described herein comprising reducing a compound of formula (II) as described herein with hydrogen in the presence of a palladium catalyst and a solvent wherein the solvent is a polar aprotic solvent or a C3-C10 alcohol. The present invention also relates to hydrochloride salts and monohydrochloride salts of the compounds of formula (I) as described herein and processes for their preparation. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of PCT application PCT / EP2019 / 066381, filed on June 20, 2019, with the invention name “Method for Preparing Aminodiaryl Ethers and Aminodiaryl Ether Hydrochlorides”. The date on which the PCT application entered the Chinese national phase is December 18, 2020, and the application number is 201980041500.0. Field of the Invention

[0002] The present invention relates to a process which can be used to prepare aminodiaryl ethers of formula (I), in particular 6-(4-(tert-butyl)phenoxy)pyridin-3-amine (formula (Ia)).

[0003] The present invention also relates to the hydrochloride of the compound of formula (I), in particular the monohydrochloride of the compound of formula (I), and to a method for preparing the monohydrochloride of the compound of formula (I), in particular the monohydrochloride of 6-(4-(tert-butyl)phenoxy)pyridin-3-amine (formula (Ia)). Background of the Invention

[0004] The compound of formula (I) is a regulator of the Notch signaling pathway, can be used to treat and / or prevent cancer, in particular can be used to treat and / or prevent Notch-dependent cancers, and can be prepared using the method disclosed in WO2013 / 093885. The method disclosed in WO2013 / 093885 has the following defects: (i) the compound of formula (I) obtained by the method is contaminated by the catalyst used; and (ii) side reactions occur, resulting in further contamination of the compound of formula (I) by by-products. These defects affect, for example, the physical appearance and solubility of the compound of formula (I), as well as subsequent preparation steps, such as grinding. In summary, the method described in WO2013 / 093885 is not suitable for large-scale preparation of pharmaceutical-grade compounds of formula (I). Therefore, it would be beneficial to develop alternative or improved methods for preparing compounds of formula (I) that do not have some or all of these defects. SUMMARY OF THE INVENTION

[0005] It has now surprisingly been found that the contamination of the compounds of formula (I) is eliminated by preparing them via a process comprising catalytic hydrogenation using a palladium catalyst in a solvent, wherein the solvent is a polar aprotic solvent or a C3-C10 alcohol. The process of the invention has been found to be reliable and applicable on an industrial scale, and the compounds of formula (I) obtained by the process of the invention consistently have an unprecedentedly high level of purity (99.9% by HPLC, Pd-content <1 ppm, as determined by elemental analysis).

[0006] The inventors surprisingly found that when the compound of formula (I) was converted into its hydrochloride, a stable salt was obtained, while all attempts to form other acid addition salts failed. The inventors further surprisingly found that when the compound of formula (I) was converted into its monohydrochloride, the purity level was further improved, i.e. the monohydrochloride was typically obtained as a colorless crystalline solid, while the color of the corresponding free base varied from batch to batch (colorless to light red range), regardless of the analytical level of purity.

[0007] The compounds disclosed in WO2013 / 093885, such as 6-(4-(tert-butyl)phenoxy)pyridin-3-amine (Formula (Ia)), have a relatively low melting point, for example, of 92.0°C ( Figure 2 ), which poses a certain risk to the physical stability of the compound during its preparation, grinding, storage and processing into pharmaceutical preparations. However, it was surprisingly found that the monohydrochloride salt of the compound of formula (I), such as 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride (Formula (Ia)), has a significantly higher melting point than the free base (e.g. 173°C, Figure 1 ). Thus, surprisingly, the monohydrochloride salt of the compound of formula (I) has improved properties relative to the compound of formula (I) in its free base form, such as a higher melting point, improved solubility in aqueous media and discrete polymorphs (according to XRPD).

[0008] In view of these surprising findings, namely the high level of purity of the compound of formula (I) achieved by the process of the present invention and the advantageous properties of the compound of formula (I), especially the monohydrochloride salt of the compound of formula (I), the inventors herein provide the present invention in the following aspects.

[0009] In a first aspect, the present invention provides a process for preparing a compound of formula (I),

[0010]

[0011] wherein X is selected from O and NH; and

[0012] where Y 1 , Y 2 and Y 3 are each independently selected from N and CH; and

[0013] Where R 1 and R 2 are each independently selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and

[0014] Where R 3 and R 4 are each independently selected from H, halogen and C1-C10 alkyl,

[0015] The method includes:

[0016] Reducing the compound of formula (II) with hydrogen in the presence of a palladium catalyst and a solvent, wherein the solvent is a polar aprotic solvent or a C3-C10 alcohol,

[0017]

[0018] wherein X is selected from O and NH; and

[0019] where Y 1 , Y 2 and Y 3 are each independently selected from N and CH; and

[0020] Where R 11 and R 22 are each independently selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and

[0021] Where R 33 and R 44 Each is independently selected from H, halogen and C1-C10 alkyl;

[0022] To form the compound of formula (I).

[0023] In a second aspect, the present invention provides a process for preparing the hydrochloride salt of a compound of formula (I),

[0024]

[0025] wherein X is selected from O and NH; and

[0026] where Y 1 , Y 2 and Y 3 are each independently selected from N and CH; and

[0027] Where R 1 and R 2 are each independently selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and

[0028] Where R 3 and R 4 are each independently selected from H, halogen and C1-C10 alkyl,

[0029] The method comprises reacting the compound of formula (I) with hydrochloric acid.

[0030] In a third aspect, the present invention provides a method for preparing a hydrochloride salt of a compound of formula (I),

[0031]

[0032] wherein X is selected from O and NH; and

[0033] where Y 1 , Y 2 and Y 3 are each independently selected from N and CH; and

[0034] Where R 1 and R 2 are each independently selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and

[0035] Where R 3 and R 4 are each independently selected from H, halogen and C1-C10 alkyl,

[0036] The method comprises reacting the compound of formula (I) with less than 1.5 molar equivalents of hydrochloric acid.

[0037] In a fourth aspect, the present invention provides the hydrochloride salt of a compound of formula (I) as defined herein.

[0038] In a fifth aspect, the present invention provides the monohydrochloride salt of a compound of formula (I) as defined herein.

[0039] In a sixth aspect, the present invention provides the hydrochloride salt of a compound of formula (I) as defined herein for use as a medicament.

[0040] In a seventh aspect, the present invention provides the monohydrochloride salt of a compound of formula (I) as defined herein for use as a medicament.

[0041] In an eighth aspect, the present invention provides the hydrochloride salt of a compound of formula (I) as defined herein for use in a method of treating and / or preventing cancer.

[0042] In a ninth aspect, the present invention provides a monohydrochloride salt of a compound of formula (I) as defined herein for use in a method of treating and / or preventing cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] The present invention is described in detail below with reference to the accompanying drawings, in which:

[0044] Figure 1 The differential scanning calorimetry thermogram (DSC) of the monohydrochloride salt of the compound of formula (Ia), 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride, is shown. The DSC thermogram shows that 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride has a melting point starting at 170.9° C. and peaking at 173.4° C.

[0045] Figure 2The DSC thermogram of the compound of formula (Ia), 6-(4-(tert-butyl)phenoxy)pyridin-3-amine, is shown. The DSC thermogram shows that the compound of formula (Ia) has a melting point that starts at 90.8°C and peaks at 92.0°C.

[0046] Figure 3 The X-ray powder diffraction (XRPD) diffraction pattern of the monohydrochloride salt of the compound of formula (Ia), 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride, is shown.

[0047] Figure 4 The HPLC chromatogram of the compound of formula (Ia), 6-(4-(tert-butyl)phenoxy)pyridin-3-amine (purity: 99.9%) obtained by the process of the present invention is shown (see Example 3A).

[0048] Figure 5 A reference HPLC chromatogram of the compound of formula (Ia), 6-(4-(tert-butyl)phenoxy)pyridin-3-amine, obtained by the method described in WO2013 / 093885 is shown (Example 2).

[0049] Figure 6 The DSC thermogram of the material obtained when 6-(4-(tert-butyl)phenoxy)pyridin-3-amine (Formula (Ia)) is reacted with greater than 1.5 molar equivalents of hydrochloric acid is shown (Example 5). The DSC thermogram shows that the material does not have a sharp melting point and suggests the presence of at least two species. DETAILED DESCRIPTION OF THE INVENTION

[0050] The present invention is described and exemplified in further detail below.

[0051] definition

[0052] The term "about" refers to + / - 10% of the specified measured value.

[0053] The term "polar aprotic solvent" refers to a solvent that does not contain an acidic hydrogen (Morrison and Boyd, Organic Chemistry 3rd Edition, 31 (1974)) and that is T The (30)-scale has a polarity of about 36 kcal / mol to about 49 kcal / mol (C. Reichardt, Chem. Rev. 1994, 94, 2319-2358; C. Reichardt, G. Liebigs Ann.1995,1579-1582; ​​R.Eberhardt,S. B. Neidhart, C. Reichardt, Liebigs Ann. / Recueil 1997, 1195-1199; C. Reichardt, Green Chem. 2005, 7, 339-351; VG Machado, RI Stock, C. Reichardt, Chem. Rev. 2014, 114, 10429-10475.) solvent. When the atom connected to the proton is nitrogen or oxygen, the interaction of providing or accepting protons is generally the greatest. This behavior is attributed to hydrogen bonding. In general, the strength of hydrogen bonding increases with the acidity of the proton-providing group and the basicity of the proton-accepting group. Polar aprotic solvents suitable for the present invention are those that do not contain acidic or basic functional groups and do not degrade into acids or bases, including but not limited to ketones, nitriles, substituted aromatic compounds such as halogenated aromatic compounds, amides, sulfoxides, alkyl carbonates, chlorinated aliphatic compounds, aromatic aldehydes, sulfones, esters, etc. or mixtures thereof. Preferred polar aprotic solvents for use in the present invention include, but are not limited to, acetone, 2-butanone, 3-methyl-2-butanone, cyclohexanone, acetonitrile, chlorobenzene, dichloromethane, chloroform, trichloroethane, ethylene chloride, benzaldehyde, sulfolane, ethyl acetate, propyl acetate, amyl acetate, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide, diethyl carbonate, propylene carbonate, ethylene carbonate, methyl ethyl ketone, methyl isopropyl ketone, methyl isobutyl ketone, and mixtures thereof. A variety of other solvents having the above-mentioned polar and aprotic properties are known to those skilled in the art.

[0054] The term "C3-C10 alcohol" refers to an unsubstituted straight or branched alkanol group containing 3 to 10 carbon atoms, preferably an unsubstituted straight or branched alkanol group containing 3 to 5 carbon atoms, such as 1-propanol, 2-propanol, 2-butanol, 2-methyl-1-propanol or 2-methylpropan-2-ol, more preferably 2-butanol or 2-propanol, and most preferably 2-propanol.

[0055] The term "non-polar solvent" refers to a solvent T (30)-scale having a polarity of less than about 35 kcal / mol. Preferred non-polar solvents for use in the present invention include, but are not limited to, pentane, hexane, heptane, cyclohexane and toluene, particularly heptane. When the non-polar solvent is, for example, a C5-C8 alkane, such as pentane, hexane or heptane, the C5-C8 alkane may be isomerically pure (e.g., n-pentane, n-hexane or n-heptane) or a random mixture of constitutional isomers.

[0056] The term "protic solvent" refers to a solvent comprising a proton-donating group. A non-limiting example of a protic solvent is, for example, water.

[0057] The expression "Tout" refers to the external temperature measured outside the reactor, and the expression "Ti" refers to the internal temperature measured inside the reactor. When the reaction temperature is indicated without specifying "Tout" or "Ti", it is understood to be the temperature measured outside the reactor.

[0058] The term "alkyl" refers to an unsubstituted straight or branched chain alkyl group, preferably an unsubstituted straight or branched chain alkyl group containing 1 to 10 carbon atoms ("C1-C10 alkyl group"), and more preferably an unsubstituted straight or branched chain alkyl group containing 3 to 8 carbon atoms ("C3-C8 alkyl group"). Non-limiting examples of alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, and 1,1-dimethylbutyl. A particularly preferred alkyl group is tert-butyl.

[0059] The term "halogen" refers to fluorine, chlorine, bromine or iodine.

[0060] The term "cycloalkyl" refers to an unsubstituted monocyclic, bicyclic, tricyclic or tetracyclic hydrocarbon radical of 3 to 12 carbon atoms ("C3-C12 cycloalkyl"), preferably 5 to 10 carbon atoms ("C5-C10 cycloalkyl"). Non-limiting examples of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and adamantyl. Particularly preferred cycloalkyls are cyclohexyl and adamantyl.

[0061] The term "activated carbon" refers to a form of carbon that has been treated to have smaller, small-volume pores, which increases the surface area available for adsorption or chemical reactions. 2 / g surface area. Typically, the surface area of ​​activated carbon is about 1000m 2 / g, but up to 3000m 2 Non-limiting examples of activated carbon are activated carbon having an iodine absorption of >70 mL / g (0.05 mol I2 / I) and / or a methylene blue absorption of >12 mL / 0.1 g (0.15% sol.) or an iodine absorption of 1200 mg / g and / or a methylene blue absorption of 255 mg / g.

[0062] The term "base" refers to a compound that deprotonates another compound when reacting with another compound. Suitable bases for the present disclosure include, but are not limited to, for example, tertiary amines, organolithium compounds, and alkaline alkali metal salts and hydrides. Examples of tertiary amines include triethylamine, N-methylmorpholine, and diisopropylethylamine. Examples of organolithium compounds include methyl lithium (CH3Li, MeLi), n-butyl lithium (n-BuLi), sec-butyl lithium (sec-BuLi), and tert-butyl lithium (tert-BuLi). Examples of alkaline alkali metal hydrides and salts include, for example, sodium hydride (NaH), potassium hydride (KH), sodium carbonate (Na2CO3), potassium carbonate (K2CO3), sodium bicarbonate (NaHCO3), sodium and potassium alkoxides, including but not limited to sodium tert-butoxide and potassium tert-butoxide, sodium propoxide and potassium propoxide, sodium isopropoxide and potassium isopropoxide, sodium ethoxide and potassium ethoxide, sodium methoxide and potassium methoxide, etc., sodium amide (NaNH2), potassium amide (KNH2), etc. Preferred bases are MeLi, K2CO3 and Na2CO3.

[0063] The term "hydrochloride salt" refers to a compound of formula (I) or (Ia), respectively, wherein the compound of formula (I) or (Ia) is protonated and the counter ion is chloride (Cl - ) and comprises monochloride salts and / or dichloride salts, in particular a mixture of monochloride salts and dichloride salts.

[0064] The term "monohydrochloride salt" refers to a compound of formula (I) or (Ia), respectively, wherein the compound of formula (I) or (Ia) is protonated once and the counter ion is chloride (Cl - ). Therefore, the stoichiometry of the mono-protonated compound of formula (I) or (Ia) and the chloride ion is 1:1.

[0065] The term "purity" is expressed as a percentage (%) and is calculated from the HPLC chromatogram recorded at 220 nm according to the following formula:

[0066] The purity of the compound of formula (I) = (A I / A x )×100

[0067] Among them A I is the peak area corresponding to the compound of formula (I), for example, the compound of formula (Ia), and A x It is the sum of the areas of other peaks observed in the HPLC chromatogram.

[0068] Process for preparing the compound of formula (I)

[0069] In a first aspect, the present invention provides a process for preparing a compound of formula (I),

[0070]

[0071] wherein X is selected from O and NH; and

[0072] where Y 1 , Y 2 and Y 3 are each independently selected from N and CH; and

[0073] Where R 1 and R 2 are each independently selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and

[0074] Where R 3 and R 4 are each independently selected from H, halogen and C1-C10 alkyl,

[0075] The method includes:

[0076] Reducing the compound of formula (II) with hydrogen in the presence of a palladium catalyst and a solvent, wherein the solvent is a polar aprotic solvent or a C3-C10 alcohol,

[0077]

[0078] wherein X is selected from O and NH; and

[0079] where Y 1 , Y 2 and Y 3 are each independently selected from N and CH; and

[0080] Where R 11 and R 22 are each independently selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and

[0081] Where R 33 and R 44 Each is independently selected from H, halogen and C1-C10 alkyl;

[0082] To form the compound of formula (I).

[0083] In one embodiment, there is provided a method according to the first aspect of the present invention, wherein the palladium catalyst is palladium-coated activated carbon.

[0084] In a preferred embodiment, a method according to the first aspect of the present invention is provided, wherein the palladium catalyst is palladium-coated activated carbon, which is selected from palladium-coated activated carbon containing about 10% wt / wt palladium and palladium-coated activated carbon containing about 5% wt / wt palladium, in particular palladium-coated activated carbon containing about 5% wt / wt palladium.

[0085] In one embodiment, the method of the first aspect of the present invention is provided, wherein the compound of formula (II) is reduced to obtain a compound of formula (I), comprising:

[0086] (a) providing a solution of a compound of formula (II) in a solvent, wherein the solvent is a polar aprotic solvent or a C3-C10 alcohol; then

[0087] (b) adding a palladium catalyst to the solution of step (a); and

[0088] (c) contacting the mixture obtained in step (b) with hydrogen;

[0089] The palladium catalyst added in step (b) is added as a dry powder, or as a suspension in the solvent used in step (a), preferably as a suspension in the solvent used in step (a).

[0090] In another embodiment, a process according to the first aspect of the invention is provided, wherein the amount of palladium relative to the compound of formula (II) is less than 7 mol%, preferably less than about 6 mol%, more preferably less than about 5 mol%, more preferably less than about 4 mol%, more preferably less than about 3 mol%, more preferably less than about 2 mol%, and in particular about 1.25 mol%.

[0091] In another embodiment, a process according to the first aspect of the invention is provided, wherein the amount of palladium relative to the compound of formula (II) is less than 7 mol% and equal to or higher than 1 mol%, preferably less than about 6 mol% and equal to or higher than 1 mol%, more preferably less than about 5 mol% and equal to or higher than 1 mol%, more preferably less than about 4 mol% and equal to or higher than 1 mol%, more preferably less than about 3 mol% and equal to or higher than 1 mol%, more preferably less than about 2 mol% and equal to or higher than 1 mol, and in particular about 1.25 mol%.

[0092] In a preferred embodiment, a method according to the first aspect of the present invention is provided, wherein the solvent is selected from the group consisting of 2-propanol, acetone, 2-butanone, 3-methyl-2-butanone, cyclohexanone, acetonitrile, chlorobenzene, dichloromethane, chloroform, trichloroethane, ethylene chloride, benzaldehyde, sulfolane, ethyl acetate, propyl acetate, amyl acetate, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide, diethyl carbonate, propylene carbonate, ethylene carbonate, methyl ethyl ketone, methyl isopropyl ketone, methyl isobutyl ketone and mixtures thereof.

[0093] In another preferred embodiment, a method according to the first aspect of the present invention is provided, wherein the solvent is selected from the group consisting of 2-propanol, acetone, 2-butanone, 3-methyl-2-butanone, cyclohexanone, acetonitrile, chlorobenzene, dichloromethane, chloroform, trichloroethane, ethylene chloride, benzaldehyde, sulfolane, ethyl acetate, propyl acetate, amyl acetate, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide, diethyl carbonate, propylene carbonate, ethylene carbonate and mixtures thereof.

[0094] In a more preferred embodiment, there is provided a method according to the first aspect of the invention, wherein the solvent is a polar aprotic solvent.

[0095] In an even more preferred embodiment, there is provided a process according to the first aspect of the invention, wherein the solvent is selected from the group consisting of acetone, 2-butanone, 3-methyl-2-butanone, cyclohexanone, acetonitrile, chlorobenzene, dichloromethane, chloroform, trichloroethane, ethylene chloride, benzaldehyde, sulfolane, ethyl acetate, propyl acetate, amyl acetate, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide, diethyl carbonate, propylene carbonate, ethylene carbonate, methyl ethyl ketone, methyl isopropyl ketone, methyl isobutyl ketone and mixtures thereof.

[0096] In another even more preferred embodiment, a process according to the first aspect of the invention is provided, wherein the solvent is selected from the group consisting of acetone, 2-butanone, 3-methyl-2-butanone, cyclohexanone, acetonitrile, chlorobenzene, dichloromethane, chloroform, trichloroethane, ethylene chloride, benzaldehyde, sulfolane, ethyl acetate, propyl acetate, amyl acetate, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide, diethyl carbonate, propylene carbonate, ethylene carbonate and mixtures thereof.

[0097] In a particularly preferred embodiment, there is provided a method according to the first aspect of the invention, wherein the solvent is ethyl acetate or 2-propanol.

[0098] In a more particularly preferred embodiment, there is provided a process according to the first aspect of the present invention, wherein the solvent is ethyl acetate.

[0099] The inventors surprisingly found that the process of the present invention enables a shorter reaction time than the prior art process described in WO 2013 / 093885.

[0100] Therefore, in one embodiment, a method according to the first aspect of the present invention is provided, wherein the reduction of the compound of formula (II) to the compound of formula (I) is completed after 1-3 hours, preferably after 1.5-3 hours, more preferably after 2-3 hours, for example after 2.5 hours, preferably when 1.2 kg of compound of formula (II) is used.

[0101] In another embodiment, a method according to the first aspect of the present invention is provided, wherein the reduction of the compound of formula (II) to the compound of formula (I) is completed after 0.5-1.5 hours, preferably after 40 minutes, preferably when 300 g of the compound of formula (II) is used.

[0102] In another embodiment, there is provided a method according to the first aspect of the invention, further comprising contacting the compound of formula (I) with activated carbon.

[0103] In another embodiment, there is provided a method according to the first aspect of the invention, further comprising crystallizing the compound of formula (I).

[0104] In a preferred embodiment, there is provided a method according to the first aspect of the present invention, further comprising contacting the compound of formula (I) with activated carbon; and crystallizing the compound of formula (I).

[0105] In another embodiment, the method of the first aspect of the present invention is provided, further comprising crystallizing the compound of formula (I), wherein the crystallization comprises precipitating the compound of formula (I) in crystalline form from a solvent mixture, the solvent mixture comprising a solvent as described herein, preferably a polar aprotic solvent and a non-polar solvent used for reducing the compound of formula (II).

[0106] In a preferred embodiment, there is provided a method according to the first aspect of the invention, further comprising crystallizing the compound of formula (I), wherein the crystallization comprises precipitating the compound of formula (I) in crystalline form from a solvent mixture comprising ethyl acetate and heptane.

[0107] In another embodiment, a method according to the first aspect of the present invention is provided, wherein the starting material of formula (II) is obtained by the following method, which comprises making a compound of formula (III)

[0108]

[0109] Where X 1 is selected from OH and NH2; and

[0110] Where R 11 and R 22 Each is independently selected from H, C1-C10 alkyl and C3-C12 cycloalkyl,

[0111] reacting with a compound of formula (IV) in the presence of a base,

[0112]

[0113] wherein LG is a leaving group; and

[0114] where Y 1 , Y2 and Y 3 are each independently selected from N and CH; and

[0115] Where R 33 and R 44 Each is independently selected from H, halogen and C1-C10 alkyl;

[0116] The raw material of formula (II) is formed, wherein X is O or NH, wherein R 11 and R 22 As defined for compounds of formula (III); and wherein R 33 , R 44 , Y 1 , Y 2 and Y 3 As defined for the compound of formula (IV); and optionally further comprising crystallizing the starting material of formula (II).

[0117] In one embodiment, the leaving group G is selected from F, Cl, Br, mesylate, tosylate and triflate. Preferably, the leaving group LG is selected from F, Cl and Br.

[0118] In a preferred embodiment, a method according to the first aspect of the present invention is provided, wherein the starting material of formula (II) is obtained by the following method, which comprises reacting a compound of formula (III) as defined above with a compound of formula (IV) as defined above in the presence of a base in a polar aprotic solvent, preferably the polar aprotic solvent is selected from dimethyl sulfoxide (DMSO), dimethylformamide (DMF) or a mixture thereof, most preferably DMSO, to form the starting material of formula (II).

[0119] In a preferred embodiment, a method according to the first aspect of the present invention is provided, wherein the raw material of formula (II) is obtained by the following method, which comprises reacting a compound of formula (III) as defined above with a compound of formula (IV) as defined above in the presence of a base to form the raw material of formula (II), and optionally further comprises crystallizing the raw material of formula (II), wherein the base is selected from potassium carbonate (K2CO3), sodium carbonate (Na2CO3), cesium carbonate (Cs2CO3), NEt3, Hünigs base and 1,8-diazabicyclo[5.4.0]11-7-ene (DBU), preferably selected from potassium carbonate (K2CO3), sodium carbonate (Na2CO3) and cesium carbonate (Cs2CO3). More preferably, the base is potassium carbonate (K2CO3).

[0120] In another preferred embodiment, a method according to the first aspect of the present invention is provided, wherein the starting material of formula (II) is obtained by the following method, which comprises reacting a compound of formula (III) as defined above with a compound of formula (IV) as defined above in the presence of a base in a polar aprotic solvent, preferably the polar aprotic solvent is selected from dimethyl sulfoxide (DMSO), dimethylformamide (DMF) or a mixture thereof, most preferably DMSO, to form the starting material of formula (II); and optionally further comprises crystallizing the starting material of formula (II), wherein the crystallization comprises precipitating the starting material of formula (II) in a crystalline form from a solvent mixture comprising a polar aprotic solvent and a non-polar solvent, preferably from a solvent mixture comprising ethyl acetate and heptane.

[0121] In a particularly preferred embodiment, there is provided a method according to the first aspect of the present invention, wherein the compound of formula (I) is 6-(4-(tert-butyl)phenoxy)pyridin-3-amine (formula (Ia));

[0122]

[0123] and wherein the compound of formula (II) is 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (formula (IIa));

[0124]

[0125] And optionally, the raw material of formula (IIa) is obtained by the following method, which comprises making 4-(tert-butyl)-phenol (formula (IIIa))

[0126]

[0127] Reaction with 2-chloro-5-nitro-pyridine (formula (IVa)) in the presence of a base,

[0128]

[0129] Forming 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (Formula (IIa)), and optionally further comprising crystallizing the 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (Formula (IIa)).

[0130] Therefore, the present invention provides a process for preparing a compound of formula (Ia),

[0131]

[0132] The method includes:

[0133] Reducing the compound of formula (IIa) with hydrogen in the presence of a palladium catalyst and a solvent, wherein the solvent is a polar aprotic solvent or a C3-C10 alcohol,

[0134]

[0135] The compound of formula (Ia) is formed.

[0136] In another particularly preferred embodiment, there is provided a method according to the first aspect of the present invention,

[0137] wherein the compound of formula (I) is 6-(4-(tert-butyl)phenoxy)pyridin-3-amine (formula (Ia)); and

[0138] The raw material of formula (II) is 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (formula (IIa)); and

[0139] The starting material of formula (IIa) is obtained by the following method, which comprises reacting 4-(tert-butyl)-phenol (formula (IIIa)) with 2-chloro-5-nitro-pyridine (formula (IVa)) in the presence of a base to form 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (formula (IIa)); and

[0140] It also includes crystallizing the 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (Formula (IIa), wherein the 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (Formula (IIa)) is precipitated in a crystalline form from a solvent mixture comprising ethyl acetate and heptane.

[0141] In another particularly preferred embodiment of the first aspect of the present invention, the present invention provides a method for preparing 6-(4-(tert-butyl)phenoxy)pyridine-3-amine (Formula (Ia)), which comprises reducing 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (Formula (IIa)) with hydrogen in the presence of palladium-coated activated carbon and ethyl acetate to form 6-(4-(tert-butyl)phenoxy)pyridine-3-amine (Formula (Ia)).

[0142] In another particularly preferred embodiment of the first aspect of the present invention, the present invention provides a method for preparing 6-(4-(tert-butyl)phenoxy)pyridine-3-amine (Formula (Ia)), which comprises reducing 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (Formula (IIa)) with hydrogen in the presence of palladium-coated activated carbon and ethyl acetate to form 6-(4-(tert-butyl)phenoxy)pyridine-3-amine (Formula (Ia)); wherein the amount of palladium relative to the compound of formula (IIa) is less than 7 mol%, preferably less than about 6 mol%, more preferably less than about 5 mol%, more preferably less than about 4 mol%, more preferably less than about 3 mol%, more preferably less than about 2 mol%, and especially about 1.25 mol%.

[0143] In another particularly preferred embodiment of the first aspect of the present invention, the present invention provides a method for preparing 6-(4-(tert-butyl)phenoxy)pyridine-3-amine (Formula (Ia)), which comprises reducing 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (Formula (IIa)) with hydrogen in the presence of palladium-coated activated carbon and ethyl acetate to form 6-(4-(tert-butyl)phenoxy)pyridine-3-amine (Formula (Ia)); wherein the amount of palladium relative to the compound of formula (IIa) is less than 7 mol% and equal to or higher than 1 mol%, preferably less than about 6 mol% and equal to or higher than 1 mol%, more preferably less than about 5 mol% and equal to or higher than 1 mol%, more preferably less than about 4 mol% and equal to or higher than 1 mol%, more preferably less than about 3 mol% and equal to or higher than 1 mol%, more preferably less than about 2 mol% and equal to or higher than 1 mol, and especially about 1.25 mol%.

[0144] In another particularly preferred embodiment of the first aspect of the present invention, the present invention provides a method for preparing 6-(4-(tert-butyl)phenoxy)pyridine-3-amine (Formula (Ia)), which comprises reducing 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (Formula (IIa)) with hydrogen in the presence of palladium activated carbon and ethyl acetate to form 6-(4-(tert-butyl)phenoxy)pyridine-3-amine (Formula (Ia));

[0145] The method of reducing 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (Formula (IIa)) with hydrogen comprises:

[0146] (a) providing a solution of 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (Formula (IIa)) in ethyl acetate; then

[0147] (b) adding palladium-coated activated carbon to the solution of step (a); and

[0148] (c) contacting the suspension obtained in step (b) with hydrogen;

[0149] The palladium-coated activated carbon added in step (b) is added as a dry powder or as a suspension in ethyl acetate, preferably as a suspension in ethyl acetate.

[0150] Compound of formula (I)

[0151] Preferably, the group NH2 is located relative to the group having the group Y 1 , Y 2 and Y 3 Preferably, the group R 1 or R 2 Located relative to the non-group Y 1 , Y2 and Y 3 The 3-position (meta-position) or 4-position (para-position) of the ring group X is preferably R 1 Located relative to the non-group Y 1 , Y 2 and Y 3 The ring group X is at the 4-position (para position), and R 2 is H, and even more preferably R 1 is H, and R 2 Located relative to the 1 , Y 2 and Y 3 Preferably, the group R 3 or R 4 Located relative to the Y 1 , Y 2 and Y 3 The 2-position (ortho position) of the ring group X (provided that Y 2 and / or Y 1 More preferably, R 3 Located relative to the Y 1 , Y 2 and Y 3 The 2-position (ortho position) of the ring group X (provided that Y 2 and / or Y 1 is C), and R 4 is H, and even more preferably R 3 is H, and R 4 Located relative to the Y 1 , Y 2 and Y 3 The 2-position (ortho position) of the ring group X (provided that Y 2 and / or Y 1 is C). Preferably, the group R 11 or R 22 Located relative to the 1 , Y 2 and Y 3 The 3-position (meta-position) or 4-position (para-position) of the ring group X is preferably R 11 Located relative to the 1 , Y 2 and Y 3 The ring group X is at the 4-position (para position), and R 22 is H, and even more preferably R 11 is H, and R 22 Located relative to the 1 , Y 2 and Y 3 Preferably, the group R33 or R 43 Located relative to the group Y 1 , Y 2 and Y 3 The 2-position (ortho position) of the ring group X (provided that Y 2 and / or Y 1 C), more preferably R 33 Located relative to the group Y 1 , Y 2 and Y 3 The 2-position (ortho position) of the ring group X (provided that Y 2 and / or Y 1 is C), and R 44 is H, and even more preferably R 33 is H, and R 43 Located relative to the group Y 1 , Y 2 and Y 3 The 2-position (ortho position) of the ring group X (provided that Y 2 and / or Y 1 is C).

[0152] In a preferred embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I), X is O; and wherein for the compound of formula (II), X is O.

[0153] In another embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0154] Y 1 , Y 2 and Y 3 are each selected from N and CH, wherein Y 1 , Y 2 and Y 3 At least one of is CH; and

[0155] Wherein for the compound of formula (II), Y 1 , Y 2 and Y 3 are each selected from N and CH, wherein Y 1 , Y 2 and Y 3 At least one of them is CH.

[0156] In another embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0157] Y 1 , Y 2 and Y 3are each selected from N and CH, wherein Y 1 and Y 3 At least one of is CH; and

[0158] Wherein for the compound of formula (II), Y 1 , Y 2 and Y 3 are each selected from N and CH, wherein Y 1 and Y 3 At least one of them is CH.

[0159] In a preferred embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0160] Y 1 is selected from N and CH; and

[0161] Y 2 and Y 3 each is CH; and

[0162] Wherein for the compound of formula (II),

[0163] Y 1 is selected from N and CH; and Y 2 and Y 3 Each is CH.

[0164] In a more preferred embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I), Y 1 is N; and

[0165] Y 2 and Y 3 each is CH; and

[0166] Wherein for the compound of formula (II),

[0167] Y 1 is N; and Y 2 and Y 3 Each is CH.

[0168] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I), R 1 and R 2 Each is independently selected from H and C1-C10 alkyl; and wherein for the compound of formula (II), R 11 and R 22 Each is independently selected from H and C1-C10 alkyl.

[0169] In another embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I), R1 and R 2 Each is independently selected from H and C3-C12 cycloalkyl; and wherein for the compound of formula (II), R 11 and R 22 Each is independently selected from H and C3-C12 cycloalkyl.

[0170] In a preferred embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I), R 1 is H, and R 2 is selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and wherein for the compound of formula (II), R 11 is H, and R 22 Selected from H, C1-C10 alkyl and C3-C12 cycloalkyl.

[0171] In another preferred embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I), R 1 is H, and R 2 is selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl and adamantyl; and wherein for the compound of formula (II), R 11 is H, and R 22 is selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl and adamantyl.

[0172] In a particularly preferred embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I), R 1 is H, and R 2 is tert-butyl; and wherein for the compound of formula (II), R 11 is H, and R 22 It is tert-butyl.

[0173] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I), R 3 and R 4 are each independently selected from H and halogen; and wherein for the compound of formula (II), R 33 and R 44 are each independently selected from H and halogen.

[0174] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I), R3 and R 4 are halogen, preferably fluorine; and wherein for the compound of formula (II), R 33 and R 44 All are halogen, preferably fluorine.

[0175] In a preferred embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I), R 3 is H, and R 4 is selected from H and halogen, preferably selected from H and fluorine; and wherein for the compound of formula (II), R 33 is H, and R 44 is selected from H and halogen, preferably selected from H and fluorine.

[0176] In a particularly preferred embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I), R 3 and R 4 are all H; and wherein for the compound of formula (II), R 33 and R 44 Both are H.

[0177] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0178] X is selected from O and NH; and

[0179] Y 1 , Y 2 and Y 3 are each selected from N and CH, wherein Y 1 , Y 2 and Y 3 At least one of is CH; and

[0180] R 1 and R 2 are each independently selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and

[0181] R 3 and R 4 are each independently selected from H and halogen; and

[0182] Wherein for the compound of formula (II),

[0183] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0184] R 11 is equal to R of the compound of formula (I) 1, R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0185] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0186] X is selected from O and NH; and

[0187] Y 1 , Y 2 and Y 3 are each selected from N and CH, wherein Y 1 and Y 3 At least one of is CH; and

[0188] R 1 and R 2 are each independently selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and

[0189] R 3 and R 4 are each independently selected from H and halogen; and

[0190] Wherein for the compound of formula (II),

[0191] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0192] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0193] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0194] X is selected from O and NH; and

[0195] Y 1 is selected from N and CH; and

[0196] Y 2 and Y3 each is CH; and

[0197] R 1 and R 2 are each independently selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and

[0198] R 3 and R 4 are each independently selected from H and halogen; and

[0199] Wherein for the compound of formula (II),

[0200] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0201] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0202] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0203] X is selected from O and NH; and

[0204] Y 1 is selected from N and CH; and

[0205] Y 2 and Y 3 each is CH; and

[0206] R 1 is H, and R 2 is selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and

[0207] R 3 and R 4 are each independently selected from H and halogen; and

[0208] Wherein for the compound of formula (II),

[0209] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0210] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0211] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0212] X is selected from O and NH; and

[0213] Y 1 is selected from N and CH; and

[0214] Y 2 and Y 3 each is CH; and

[0215] R 1 is H, and R 2 is selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and

[0216] R 3 is H, and R 4 is selected from H and halogen; and

[0217] Wherein for the compound of formula (II),

[0218] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0219] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0220] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0221] X is selected from O and NH; and

[0222] Y 1 is selected from N and CH; and

[0223] Y 2 and Y 3 each is CH; and

[0224] R 1 is H, and R 2 is selected from H, C3-C8 alkyl and C5-C10 cycloalkyl; and

[0225] R 3 is H, and R 4 is selected from H and halogen; and

[0226] Wherein for the compound of formula (II),

[0227] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0228] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0229] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0230] X is selected from O and NH; and

[0231] Y 1 is selected from N and CH; and

[0232] Y 2 and Y 3 each is CH; and

[0233] R 1 is H, and R 2 is selected from H and C3-C8 alkyl; and

[0234] R 3 is H, and R 4 is selected from H and halogen; and

[0235] Wherein for the compound of formula (II),

[0236] X, Y 1 , Y 2 and Y 3As defined for compounds of formula (I); and

[0237] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0238] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0239] X is selected from O and NH; and

[0240] Y 1 is selected from N and CH; and

[0241] Y 2 and Y 3 each is CH; and

[0242] R 1 is H, and R 2 is selected from H and C5-C10 cycloalkyl; and

[0243] R 3 is H, and R 4 is selected from H and halogen; and

[0244] Wherein for the compound of formula (II),

[0245] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0246] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0247] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0248] X is O; and

[0249] Y 1is selected from N and CH; and

[0250] Y 2 and Y 3 each is CH; and

[0251] R 1 is H, and R 2 is selected from H and C3-C8 alkyl; and

[0252] R 3 is H, and R 4 is selected from H and halogen; and

[0253] Wherein for the compound of formula (II),

[0254] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0255] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0256] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0257] X is O; and

[0258] Y 1 is selected from N and CH; and

[0259] Y 2 and Y 3 each is CH; and

[0260] R 1 is H, and R 2 is selected from H and C5-C10 cycloalkyl; and

[0261] R 3 is H, and R 4 is selected from H and halogen; and

[0262] Wherein for the compound of formula (II),

[0263] X, Y 1 , Y 2 and Y 3As defined for compounds of formula (I); and

[0264] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0265] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0266] X is NH; and

[0267] Y 1 is selected from N and CH; and

[0268] Y 2 and Y 3 each is CH; and

[0269] R 1 is H, and R 2 is selected from H and C3-C8 alkyl; and

[0270] R 3 is H, and R 4 is selected from H and halogen; and

[0271] Wherein for the compound of formula (II),

[0272] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0273] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0274] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0275] X is NH; and

[0276] Y 1is selected from N and CH; and

[0277] Y 2 and Y 3 each is CH; and

[0278] R 1 is H, and R 2 is selected from H and C5-C10 cycloalkyl; and

[0279] R 3 is H, and R 4 is selected from H and halogen; and

[0280] Wherein for the compound of formula (II),

[0281] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0282] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0283] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0284] X is selected from O and NH; and

[0285] Y 1 is selected from N and CH; and

[0286] Y 2 and Y 3 each is CH; and

[0287] R 1 and R 2 are each independently selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl and adamantyl; and

[0288] R 3 and R 4 are each independently selected from H and F; and

[0289] Wherein for the compound of formula (II),

[0290] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0291] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0292] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0293] X is selected from O and NH; and

[0294] Y 1 is selected from N and CH; and

[0295] Y 2 and Y 3 each is CH; and

[0296] R 1 is H, and R 2 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl, and adamantyl; and

[0297] R 3 and R 4 are each independently selected from H and F; and

[0298] Wherein for the compound of formula (II),

[0299] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0300] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0301] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0302] X is selected from O and NH; and

[0303] Y 1 is selected from N and CH; and

[0304] Y 2 and Y 3 each is CH; and

[0305] R 1 is H, and R 2 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl, and adamantyl; and

[0306] R 3 is H, and R 4 is selected from H and F; and

[0307] Wherein for the compound of formula (II),

[0308] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0309] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0310] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0311] X is O; and

[0312] Y 1 is N; and

[0313] Y 2 and Y 3 each is CH; and

[0314] R 1 and R 2are each independently selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl and adamantyl; and

[0315] R 3 is H, and R 4 is selected from H and F; and

[0316] Wherein for the compound of formula (II),

[0317] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0318] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0319] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0320] X is O; and

[0321] Y 1 , Y 2 and Y 3 each is CH; and

[0322] R 1 and R 2 are each independently selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl and adamantyl; and

[0323] R 3 is H, and R 4 is selected from H and F; and

[0324] Wherein for the compound of formula (II),

[0325] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0326] R11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0327] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0328] X is NH; and

[0329] Y 1 is N; and

[0330] Y 2 and Y 3 each is CH; and

[0331] R 1 and R 2 are each independently selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl and adamantyl; and

[0332] R 3 is H, and R 4 is selected from H and F; and

[0333] Wherein for the compound of formula (II),

[0334] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0335] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0336] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0337] X is NH; and

[0338] Y 1 , Y 2 and Y 3 each is CH; and

[0339] R 1 and R 2 are each independently selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl and adamantyl; and

[0340] R 3 is H, and R 4 is selected from H and F; and

[0341] Wherein for the compound of formula (II),

[0342] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0343] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0344] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0345] X is O; and

[0346] Y 1 is N; and

[0347] Y 2 and Y 3 each is CH; and

[0348] R 1 is H, and R 2 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl, and adamantyl; and

[0349] R 3 is H, and R 4 is selected from H and F; and

[0350] Wherein for the compound of formula (II),

[0351] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0352] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0353] In a preferred embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0354] X is O; and

[0355] Y 1 is N; and

[0356] Y 2 and Y 3 each is CH; and

[0357] R 1 is H, and R 2 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl, and adamantyl; and

[0358] R 3 is H, and R 4 is H; and

[0359] Wherein for the compound of formula (II),

[0360] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0361] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44is equal to R of the compound of formula (I) 4 .

[0362] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0363] X is O; and

[0364] Y 1 , Y 2 and Y 3 each is CH; and

[0365] R 1 is H, and R 2 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl, and adamantyl; and

[0366] R 3 is H, and R 4 is selected from H and F; and

[0367] Wherein for the compound of formula (II),

[0368] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0369] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0370] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0371] X is NH; and

[0372] Y 1 is N; and

[0373] Y 2 and Y 3 each is CH; and

[0374] R 1 is H, and R 2is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl, and adamantyl; and

[0375] R 3 is H, and R 4 is selected from H and F; and

[0376] Wherein for the compound of formula (II),

[0377] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0378] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0379] In one embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0380] X is NH; and

[0381] Y 1 , Y 2 and Y 3 each is CH; and

[0382] R 1 is H, and R 2 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl, and adamantyl; and

[0383] R 3 is H, and R 4 is selected from H and F; and

[0384] Wherein for the compound of formula (II),

[0385] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0386] R11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0387] In a preferred embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0388] X is selected from O and NH; and

[0389] Y 1 , Y 2 and Y 3 are each selected from N and CH; and

[0390] R 1 is H, and R 2 is tert-butyl; and

[0391] R 3 and R 4 are H; and

[0392] Wherein for the compound of formula (II),

[0393] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0394] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0395] In a preferred embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0396] X is selected from O and NH; and

[0397] Y 1 is selected from N and CH; and

[0398] Y 2 and Y 3 each is CH; and

[0399] R 1 is H, and R 2 is tert-butyl; and

[0400] R 3 and R 4 are H; and

[0401] Wherein for the compound of formula (II),

[0402] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0403] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0404] In another preferred embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0405] X is selected from O and NH; and

[0406] Y 1 is N; and

[0407] Y 2 and Y 3 each is CH; and

[0408] R 1 is H, and R 2 is tert-butyl; and

[0409] R 3 and R 4 are H; and

[0410] Wherein for the compound of formula (II),

[0411] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0412] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0413] In another preferred embodiment, the method of the first aspect of the present invention is provided, wherein for the compound of formula (I),

[0414] X is selected from O and NH; and

[0415] Y 1 , Y 2 and Y 3 each is CH; and

[0416] R 1 is H, and R 2 is tert-butyl; and

[0417] R 3 and R 4 are H; and

[0418] Wherein for the compound of formula (II),

[0419] X, Y 1 , Y 2 and Y 3 As defined for compounds of formula (I); and

[0420] R 11 is equal to R of the compound of formula (I) 1 , R 22 is equal to R of the compound of formula (I) 2 , R 33 is equal to R of the compound of formula (I) 3 , and R 44 is equal to R of the compound of formula (I) 4 .

[0421] In a particularly preferred embodiment, there is provided a method according to the first aspect of the present invention, wherein the compound of formula (I) is selected from

[0422]

[0423] 4-(4-(tert-pentyl)phenoxy)aniline,

[0424]

[0425] 4-(4-cyclohexylphenoxy)aniline,

[0426]

[0427] 6-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)pyridin-3-amine,

[0428] 6-(3-(tert-butyl)phenoxy)pyridin-3-amine,

[0429]

[0430] 4-(4-(tert-butyl)phenoxy)-3-fluoroaniline,

[0431]

[0432] 6-(4-(tert-pentyl)phenoxy)pyridin-3-amine,

[0433]

[0434] 6-(4-Butylphenoxy)pyridin-3-amine,

[0435]

[0436] 4-(4-cyclohexylphenoxy)-3-fluoroaniline,

[0437]

[0438] 3-Fluoro-4-(4-(tert-amyl)phenoxy)aniline,

[0439]

[0440] 6-(4-(2-methylpentan-2-yl)phenoxy)pyridin-3-amine,

[0441]

[0442] 4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)aniline,

[0443]

[0444] 4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)-3-fluoroaniline,

[0445]

[0446] 6-(4-cyclohexylphenoxy)pyridin-3-amine,

[0447]

[0448] 4-(4-(tert-butyl)phenoxy)aniline,

[0449]

[0450] 4-(4-isopropylphenoxy)aniline, and

[0451]

[0452] 6-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)pyridin-3-amine;

[0453] and

[0454] Wherein the compound of formula (II) is selected from the nitroaryl-analogues of compounds of formula (V)-(XX) as shown above.

[0455] In another particularly preferred embodiment, there is provided a method according to the first aspect of the present invention,

[0456] wherein the compound of formula (I) is 6-(4-(tert-butyl)phenoxy)pyridin-3-amine (formula (Ia)); and

[0457] The compound of formula (II) is 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (formula (IIa)).

[0458] The hydrochloride and monohydrochloride of the compound of formula (I)

[0459] The inventors surprisingly found that when the compound of formula (I) was converted into its hydrochloride, a stable salt was obtained, while all attempts to form other acid addition salts failed. The inventors further surprisingly found that when the compound of formula (I) was converted into its monohydrochloride, the purity level was further improved, i.e., the monohydrochloride was typically obtained as a colorless crystalline solid (see, e.g., Example 4), while the color of the free base varied from batch to batch (ranging from colorless to light red), regardless of the analytical level of purity, which was consistently and reproducibly high (99.9% purity, as determined by HPLC, Pd-content <1 ppm, as determined by elemental analysis). When providing active pharmaceutical ingredients (APIs) to the pharmaceutical industry, the consistent properties of the APIs, including their color, physical appearance, purity, solubility, and reproducibility of preparation are of paramount importance. Therefore, the monohydrochloride of the compound of formula (I) of high purity, colorless, and crystalline is particularly useful as an API, which has been highly consistent in repeated multi-kg large-scale preparations.

[0460] Further surprisingly, attempts to form other acid addition salts or the corresponding dihydrochloride salts failed (see Example 5). For example, when more than 1.5 molar equivalents of hydrochloric acid were used to form the hydrochloride salt of the compound of formula (I), a mixture of monochloride and dichloride salts with an ambiguous melting point was obtained (see Examples 5 and Figure 6 ).

[0461] Therefore, in one embodiment, a method of the first aspect of the invention is provided, further comprising reacting a compound of formula (I) or (Ia) with hydrochloric acid, typically with equal to or greater than about 1.5 molar equivalents of hydrochloric acid, preferably with equal to or greater than about 1.5 molar equivalents of hydrochloric acid and less than about 5 molar equivalents of hydrochloric acid, more preferably with equal to or greater than about 2 molar equivalents of hydrochloric acid and less than about 3 molar equivalents of hydrochloric acid, and even more preferably with about 2.5 molar equivalents of hydrochloric acid to form the hydrochloride salt of the compound of formula (I) or (Ia).

[0462] Therefore, in one embodiment, a method of the first aspect of the invention is provided, further comprising reacting a compound of formula (I) or (Ia) with less than about 1.5 molar equivalents of hydrochloric acid, typically less than about 1.5 and equal to or greater than about 1 molar equivalents of hydrochloric acid, preferably about 1.4 molar equivalents, more preferably about 1.3 molar equivalents, still more preferably about 1.2 molar equivalents, even more preferably about 1.1 molar equivalents, most preferably about 1 molar equivalents, for example about 1.01 molar equivalents of hydrochloric acid, to form a monohydrochloride salt of the compound of formula (I) or (Ia).

[0463] In a preferred embodiment, a method according to the first aspect of the present invention is provided, further comprising reacting a compound of formula (I) or (Ia) with less than about 1.5 molar equivalents of hydrochloric acid, typically less than about 1.5 and equal to or greater than about 1 molar equivalents of hydrochloric acid, preferably about 1.4 molar equivalents, more preferably about 1.3 molar equivalents, still more preferably about 1.2 molar equivalents, even more preferably about 1.1 molar equivalents, most preferably about 1 molar equivalents, for example about 1.01 molar equivalents of hydrochloric acid, to form a monohydrochloride salt of the compound of formula (I) or (Ia); wherein the reaction of the compound of formula (I) or (Ia) with hydrochloric acid is carried out in a protic solvent, preferably 2-propanol.

[0464] In one embodiment, a method according to the first aspect of the invention is provided, further comprising reacting a compound of formula (I) or (Ia) with less than about 1.5 molar equivalents of hydrochloric acid, typically less than about 1.5 and equal to or greater than about 1 molar equivalents of hydrochloric acid, preferably about 1.4 molar equivalents, more preferably about 1.3 molar equivalents, still more preferably about 1.2 molar equivalents, even more preferably about 1.1 molar equivalents, most preferably about 1 molar equivalents, for example about 1.01 molar equivalents of hydrochloric acid, to form a monohydrochloride salt of the compound of formula (I) or (Ia), and subsequently crystallizing the monohydrochloride salt.

[0465] In one embodiment, a method according to the first aspect of the invention is provided, further comprising reacting a compound of formula (I) or (Ia) with less than about 1.5 molar equivalents of hydrochloric acid, typically less than about 1.5 and equal to or greater than about 1 molar equivalents of hydrochloric acid, preferably about 1.4 molar equivalents, more preferably about 1.3 molar equivalents, still more preferably about 1.2 molar equivalents, even more preferably about 1.1 molar equivalents, most preferably about 1 molar equivalents, for example about 1.01 molar equivalents of hydrochloric acid, to form a monohydrochloride salt of the compound of formula (I) or (Ia), followed by crystallization of the monohydrochloride salt, wherein the crystallization comprises precipitating the monohydrochloride salt in a crystalline form from a solvent mixture comprising a protic solvent and a non-polar solvent, most preferably from a solvent mixture comprising 2-propanol and heptane.

[0466] In one embodiment, a method according to the first aspect of the invention is provided, further comprising crystallizing a compound of formula (I) or (Ia), and reacting the compound of formula (I) or (Ia) with less than about 1.5 molar equivalents of hydrochloric acid, typically less than about 1.5 and equal to or greater than about 1 molar equivalents of hydrochloric acid, preferably about 1.4 molar equivalents, more preferably about 1.3 molar equivalents, still more preferably about 1.2 molar equivalents, even more preferably about 1.1 molar equivalents, most preferably about 1 molar equivalents, for example about 1.01 molar equivalents of hydrochloric acid, to form a monohydrochloride salt of the compound of formula (I) or (Ia).

[0467] In one embodiment, a method of the first aspect of the invention is provided, further comprising contacting a compound of formula (I) or (Ia) with activated carbon; crystallizing the compound of formula (I) or (Ia); and crystallizing the compound of formula (I) or (Ia), and reacting the compound of formula (I) or (Ia) with less than about 1.5 molar equivalents of hydrochloric acid, typically less than about 1.5 and equal to or greater than about 1 molar equivalents of hydrochloric acid, preferably about 1.4 molar equivalents, more preferably about 1.3 molar equivalents, still more preferably about 1.2 molar equivalents, even more preferably about 1.1 molar equivalents, most preferably about 1 molar equivalents, for example about 1.01 molar equivalents of hydrochloric acid, to form a monohydrochloride salt of the compound of formula (I) or (Ia).

[0468] In one embodiment, a method according to the first aspect of the invention is provided, further comprising contacting a compound of formula (I) or (Ia) with activated carbon; crystallizing the compound of formula (I) or (Ia); and reacting the compound of formula (I) or (Ia) with less than about 1.5 molar equivalents of hydrochloric acid, typically less than about 1.5 and equal to or greater than about 1 molar equivalents of hydrochloric acid, preferably about 1.4 molar equivalents, more preferably about 1.3 molar equivalents, still more preferably about 1.2 molar equivalents, even more preferably about 1.1 molar equivalents, most preferably about 1 molar equivalents, for example about 1.01 molar equivalents of hydrochloric acid, to form a monohydrochloride salt of the compound of formula (I) or (Ia); wherein the crystallization comprises precipitating the compound of formula (I) or (Ia) in crystalline form from a solvent mixture comprising a protic solvent and a non-polar solvent, most preferably from a solvent mixture comprising 2-propanol and heptane.

[0469] In one embodiment, a method according to the first aspect of the invention is provided, further comprising crystallizing a compound of formula (I) or (Ia), and reacting the compound of formula (I) or (Ia) with less than about 1.5 molar equivalents of hydrochloric acid, typically less than about 1.5 and equal to or greater than about 1 molar equivalents of hydrochloric acid, preferably about 1.4 molar equivalents, more preferably about 1.3 molar equivalents, still more preferably about 1.2 molar equivalents, even more preferably about 1.1 molar equivalents, most preferably about 1 molar equivalents, for example about 1.01 molar equivalents of hydrochloric acid, to form a monohydrochloride salt of the compound of formula (I) or (Ia), and subsequently crystallizing the monohydrochloride salt.

[0470] In a second aspect, the present invention provides a process for preparing the hydrochloride salt of a compound of formula (I),

[0471]

[0472] wherein X is selected from O and NH; and

[0473] where Y 1 , Y 2 and Y 3 are each independently selected from N and CH; and

[0474] Where R 1 and R 2 are each independently selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and

[0475] Where R 3 and R 4 are each independently selected from H, halogen and C1-C10 alkyl,

[0476] The method comprises reacting a compound of formula (I) with hydrochloric acid, typically with equal to or greater than about 1.5 molar equivalents of hydrochloric acid, preferably with equal to or greater than about 1.5 molar equivalents of hydrochloric acid and less than about 5 molar equivalents of hydrochloric acid, more preferably with equal to or greater than about 2 molar equivalents of hydrochloric acid and less than about 3 molar equivalents of hydrochloric acid, and even more preferably with about 2.5 molar equivalents of hydrochloric acid to form the hydrochloride salt of the compound of formula (I).

[0477] In a third aspect, the present invention provides a method for preparing a hydrochloride salt of a compound of formula (I),

[0478]

[0479] wherein X is selected from O and NH; and

[0480] where Y 1 , Y 2 and Y 3 are each independently selected from N and CH; and

[0481] Where R 1 and R 2 are each independently selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and

[0482] Where R 3 and R 4 are each independently selected from H, halogen and C1-C10 alkyl,

[0483] The method comprises reacting the compound of formula (I) with less than about 1.5 molar equivalents of hydrochloric acid, typically less than about 1.5 and equal to or greater than about 1 molar equivalents of hydrochloric acid, preferably about 1.4 molar equivalents, more preferably about 1.3 molar equivalents, still more preferably about 1.2 molar equivalents, even more preferably about 1.1 molar equivalents, most preferably about 1 molar equivalents, for example about 1.01 molar equivalents of hydrochloric acid, to form a monohydrochloride salt of the compound of formula (I).

[0484] In one embodiment, there is provided a method according to the third aspect of the present invention, further comprising crystallizing the monohydrochloride salt of the compound of formula (I).

[0485] In a preferred embodiment, a method according to the third aspect of the present invention is provided, further comprising crystallizing a hydrochloride salt of the compound of formula (I), wherein the crystallization comprises precipitating the hydrochloride salt in a crystalline form from a solvent mixture comprising a protic solvent and a non-polar solvent, most preferably from a solvent mixture comprising 2-propanol and heptane.

[0486] In one embodiment there is provided a process according to the third aspect of the invention wherein the compound of formula (I) is crystallised and then reacted with hydrochloric acid.

[0487] In one embodiment, there is provided a process according to the third aspect of the invention, wherein the compound of formula (I) is contacted with activated carbon and crystallized before being reacted with hydrochloric acid.

[0488] In one embodiment, there is provided a process according to the third aspect of the invention, wherein the compound of formula (I) is contacted with activated carbon and crystallized by precipitating it in crystalline form from a solvent mixture comprising a protic solvent and a non-polar solvent, most preferably from a solvent mixture comprising 2-propanol and heptane, and then reacting it with hydrochloric acid.

[0489] In one embodiment, a method according to the third aspect of the present invention is provided, further comprising crystallizing a hydrochloride salt of the compound of formula (VI); wherein the compound of formula (I) is crystallized and then reacted with hydrochloric acid.

[0490] In one embodiment, a method according to the third aspect of the present invention is provided, further comprising crystallizing a hydrochloride salt of the compound of formula (I); wherein the compound of formula (I) is contacted with carbon-coated activated carbon and crystallized, and then reacted with hydrochloric acid.

[0491] In a preferred embodiment, there is provided a process according to the third aspect of the present invention, wherein said reacting the compound of formula (I) with hydrochloric acid is carried out in a protic solvent, preferably 2-propanol.

[0492] It has further surprisingly been found that the monohydrochloride salts of the compounds of formula (I) have improved properties compared to the free base form of the compounds of formula (I), such as a higher melting point and improved solubility in aqueous media. For example, 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride has a melting point of 173° C. (determined by DSC; see Figure 1 ), whereas the corresponding free base of formula (Ia) has a melting point of only 92° C. (determined by DSC; see Figure 2 Surprisingly, all attempts to form other acid addition salts failed (Example 5). In addition, attempts to form the corresponding dihydrochloride salt of the compound of formula (Ia) unexpectedly resulted in the formation of a material with two melting points (Example 5) ( Figure 6 ), which reveals that there are at least two types.

[0493] In a fourth aspect, the present invention provides a hydrochloride salt of a compound of formula (I),

[0494]

[0495] wherein X is selected from O and NH; and

[0496] where Y 1 , Y 2 and Y 3are each independently selected from N and CH; and

[0497] Where R 1 and R 2 are each independently selected from H, C1-C10 alkyl and C3-C12 cycloalkyl, and

[0498] Where R 3 and R 4 Each is independently selected from H, halogen and C1-C10 alkyl.

[0499] In a fifth aspect, the present invention provides a hydrochloride salt of a compound of formula (I),

[0500]

[0501] wherein X is selected from O and NH; and

[0502] where Y 1 , Y 2 and Y 3 are each independently selected from N and CH; and

[0503] Where R 1 and R 2 are each independently selected from H, C1-C10 alkyl and C3-C12 cycloalkyl, and

[0504] Where R 3 and R 4 Each is independently selected from H, halogen and C1-C10 alkyl.

[0505] In a preferred embodiment, there is provided the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride salt of the fourth and fifth aspects of the present invention, wherein for the compound of formula (I), X is selected from O and NH.

[0506] In a particularly preferred embodiment, there is provided the method of the second and third aspects of the invention or the hydrochloride and monohydrochloride salt of the fourth and fifth aspects of the invention, wherein for the compound of formula (I), X is O.

[0507] In another embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention are provided, wherein for the compound of formula (I), Y 1 , Y 2 and Y 3 are each selected from N and CH, wherein Y 1 , Y 2 and Y 3 At least one of them is CH.

[0508] In another embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention are provided, wherein for the compound of formula (I), Y 1 , Y 2 and Y 3 are each selected from N and CH, wherein Y 1 and Y 3 At least one of them is CH.

[0509] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I), Y 1 is selected from N and CH; and Y 2 and Y 3 Each is CH.

[0510] In a preferred embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I), Y 1 is N; and Y 2 and Y 3 Each is CH.

[0511] In another preferred embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention are provided, wherein for the compound of formula (I), Y 1 , Y 2 and Y 3 Each is CH.

[0512] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I), Y 1 and Y 2 are N; and Y 3 is N.

[0513] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I), Y 1 and Y 2 are N; and Y 3 For CH.

[0514] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention are provided, wherein for the compound of formula (I), R 1 and R 2Each is independently selected from H and C1-C10 alkyl.

[0515] In another embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention are provided, wherein for the compound of formula (I), R 1 and R 2 Each is independently selected from H and C3-C12 cycloalkyl.

[0516] In a preferred embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I), R 1 is H, and R 2 Selected from H, C1-C10 alkyl and C3-C12 cycloalkyl.

[0517] In another preferred embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention are provided, wherein for the compound of formula (I), R 1 is H, and R 2 is selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl and adamantyl.

[0518] In a particularly preferred embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I), R 1 is H, and R 2 It is tert-butyl.

[0519] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention are provided, wherein for the compound of formula (I), R 3 and R 4 are each independently selected from H and halogen.

[0520] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention are provided, wherein for the compound of formula (I), R 3 and R 4 All are halogen, preferably fluorine.

[0521] In a preferred embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I), R 3is H, and R 4 Selected from H and halogen, preferably selected from H and fluorine.

[0522] In a particularly preferred embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I), R 3 and R 4 Both are H.

[0523] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0524] X is selected from O and NH; and

[0525] Y 1 , Y 2 and Y 3 are each selected from N and CH, wherein Y 1 , Y 2 and Y 3 At least one of is CH; and

[0526] R 1 and R 2 are each independently selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and

[0527] R 3 and R 4 are each independently selected from H and halogen.

[0528] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0529] X is selected from O and NH; and

[0530] Y 1 , Y 2 and Y 3 are each selected from N and CH, wherein Y 1 and Y 3 At least one of is CH; and

[0531] R 1 and R 2 are each independently selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and

[0532] R 3 and R 4 are each independently selected from H and halogen.

[0533] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0534] X is selected from O and NH; and

[0535] Y 1 is selected from N and CH; and

[0536] Y 2 and Y 3 each is CH; and

[0537] R 1 and R 2 are each independently selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and

[0538] R 3 and R 4 are each independently selected from H and halogen.

[0539] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0540] X is selected from O and NH; and

[0541] Y 1 is selected from N and CH; and

[0542] Y 2 and Y 3 each is CH; and

[0543] R 1 is H, and R 2 is selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and

[0544] R 3 and R 4 are each independently selected from H and halogen.

[0545] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0546] X is selected from O and NH; and

[0547] Y 1 is selected from N and CH; and

[0548] Y 2 and Y 3 each is CH; and

[0549] R 1 is H, and R 2 is selected from H, C1-C10 alkyl and C3-C12 cycloalkyl; and

[0550] R 3 is H, and R 4 is selected from H and halogen.

[0551] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0552] X is selected from O and NH; and

[0553] Y 1 is selected from N and CH; and

[0554] Y 2 and Y 3 each is CH; and

[0555] R 1 is H, and R 2 is selected from H, C3-C8 alkyl and C5-C10 cycloalkyl; and

[0556] R 3 is H, and R 4 is selected from H and halogen.

[0557] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0558] X is selected from O and NH; and

[0559] Y 1 is selected from N and CH; and

[0560] Y 2 and Y 3 each is CH; and

[0561] R 1 is H, and R 2 is selected from H and C3-C8 alkyl; and

[0562] R 3 is H, and R 4 is selected from H and halogen.

[0563] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0564] X is selected from O and NH; and

[0565] Y 1 is selected from N and CH; and

[0566] Y 2 and Y 3 each is CH; and

[0567] R 1 is H, and R 2 is selected from H and C5-C10 cycloalkyl; and

[0568] R 3 is H, and R 4 is selected from H and halogen.

[0569] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0570] X is O; and

[0571] Y 1 is selected from N and CH; and

[0572] Y 2 and Y 3 each is CH; and

[0573] R 1 is H, and R 2 is selected from H and C3-C8 alkyl; and

[0574] R 3 is H, and R 4 is selected from H and halogen.

[0575] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0576] X is O; and

[0577] Y 1 is selected from N and CH; and

[0578] Y 2 and Y 3 each is CH; and

[0579] R 1is H, and R 2 is selected from H and C5-C10 cycloalkyl; and

[0580] R 3 is H, and R 4 is selected from H and halogen.

[0581] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0582] X is NH; and

[0583] Y 1 is selected from N and CH; and

[0584] Y 2 and Y 3 each is CH; and

[0585] R 1 is H, and R 2 is selected from H and C3-C8 alkyl; and

[0586] R 3 is H, and R 4 is selected from H and halogen.

[0587] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0588] X is NH; and

[0589] Y 1 is selected from N and CH; and

[0590] Y 2 and Y 3 each is CH; and

[0591] R 1 is H, and R 2 is selected from H and C5-C10 cycloalkyl; and

[0592] R 3 is H, and R 4 is selected from H and halogen.

[0593] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0594] X is selected from O and NH; and

[0595] Y 1 is selected from N and CH; and

[0596] Y 2 and Y 3 each is CH; and

[0597] R 1 and R 2 are each independently selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl and adamantyl; and

[0598] R 12 and R 13 are each independently selected from H and F.

[0599] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0600] X is selected from O and NH; and

[0601] Y 1 is selected from N and CH; and

[0602] Y 2 and Y 3 each is CH; and

[0603] R 1 is H, and R 2 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl, and adamantyl; and

[0604] R 3 and R 4 are each independently selected from H and F.

[0605] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0606] X is selected from O and NH; and

[0607] Y 1 is selected from N and CH; and

[0608] Y 2 and Y 3 each is CH; and

[0609] R1 is H, and R 2 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl, and adamantyl; and

[0610] R 3 is H, and R 4 Selected from H and F.

[0611] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0612] X is O; and

[0613] Y 1 is N; and

[0614] Y 2 and Y 3 each is CH; and

[0615] R 1 and R 2 are each independently selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl and adamantyl; and

[0616] R 3 is H, and R 4 Selected from H and F.

[0617] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0618] X is O; and

[0619] Y 1 , Y 2 and Y 3 each is CH; and

[0620] R 1 and R 2 are each independently selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl and adamantyl; and

[0621] R 3 is H, and R4 Selected from H and F.

[0622] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0623] X is NH; and

[0624] Y 1 is N; and

[0625] Y 2 and Y 3 each is CH; and

[0626] R 1 and R 2 are each independently selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl and adamantyl; and

[0627] R 3 is H, and R 4 Selected from H and F.

[0628] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0629] X is NH; and

[0630] Y 1 , Y 2 and Y 3 each is CH; and

[0631] R 1 and R 2 are each independently selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl and adamantyl; and

[0632] R 3 is H, and R 4 Selected from H and F.

[0633] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0634] X is O; and

[0635] Y 1 is N; and

[0636] Y 2 and Y 3 each is CH; and

[0637] R 1 is H, and R 2 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl, and adamantyl; and

[0638] R 3 is H, and R 4 Selected from H and F.

[0639] In a preferred embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0640] X is O; and

[0641] Y 1 is N; and

[0642] Y 2 and Y 3 each is CH; and

[0643] R 1 is H, and R 2 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl, and adamantyl; and

[0644] R 3 is H, and R 4 For H.

[0645] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0646] X is O; and

[0647] Y 1 , Y 2 and Y 3 each is CH; and

[0648] R 1 is H, and R 2is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl, and adamantyl; and

[0649] R 3 is H, and R 4 Selected from H and F.

[0650] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0651] X is NH; and

[0652] Y 1 is N; and

[0653] Y 2 and Y 3 each is CH; and

[0654] R 1 is H, and R 2 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl, and adamantyl; and

[0655] R 3 is H, and R 4 Selected from H and F.

[0656] In one embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0657] X is NH; and

[0658] Y 1 , Y 2 and Y 3 each is CH; and

[0659] R 1 is H, and R 2 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, 1,1-dimethylpropyl, 1,1-dimethyl-3,3-dimethylbutyl, 1,1-dimethylbutyl, cyclohexyl, and adamantyl; and

[0660] R 3 is H, and R 4 Selected from H and F.

[0661] In a preferred embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention is provided, wherein for the compound of formula (I),

[0662] X is selected from O and NH; and

[0663] Y 1 , Y 2 and Y 3 are each selected from N and CH; and

[0664] R 1 is H, and R 2 is tert-butyl; and

[0665] R 3 and R 4 Both are H.

[0666] In another preferred embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention are provided, wherein for the compound of formula (I),

[0667] X is selected from O and NH; and

[0668] Y 1 is selected from N and CH; and

[0669] Y 2 and Y 3 each is CH; and

[0670] R 1 is H, and R 2 is tert-butyl; and

[0671] R 3 and R 4 Both are H.

[0672] In another preferred embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention are provided, wherein for the compound of formula (I),

[0673] X is selected from O and NH; and

[0674] Y 1 is N; and

[0675] Y 2 and Y 3 each is CH; and

[0676] R 1 is H, and R 2 is tert-butyl; and

[0677] R 3 and R 4 Both are H.

[0678] In another preferred embodiment, the method of the second and third aspects of the present invention or the hydrochloride and monohydrochloride of the fourth and fifth aspects of the present invention are provided, wherein for the compound of formula (I),

[0679] X is selected from O and NH; and

[0680] Y 1 , Y 2 and Y 3 each is CH; and

[0681] R 1 is H, and R 2 is tert-butyl; and

[0682] R 3 and R 4 Both are H.

[0683] In a particularly preferred embodiment, there is provided a method according to the second and third aspects of the present invention or a hydrochloride salt and a monohydrochloride salt according to the fourth and fifth aspects of the present invention, wherein the compound of formula (I) is selected from

[0684]

[0685] 4-(4-(tert-Amyl)phenoxy)aniline,

[0686]

[0687] 4-(4-cyclohexylphenoxy)aniline,

[0688]

[0689] 6-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)pyridin-3-amine,

[0690]

[0691] 6-(3-(tert-butyl)phenoxy)pyridin-3-amine,

[0692]

[0693] 4-(4-(tert-butyl)phenoxy)-3-fluoroaniline,

[0694]

[0695] 6-(4-(tert-pentyl)phenoxy)pyridin-3-amine,

[0696]

[0697] 6-(4-Butylphenoxy)pyridin-3-amine,

[0698]

[0699] 4-(4-cyclohexylphenoxy)-3-fluoroaniline,

[0700]

[0701] 3-Fluoro-4-(4-(tert-amyl)phenoxy)aniline,

[0702]

[0703] 6-(4-(2-methylpentan-2-yl)phenoxy)pyridin-3-amine,

[0704]

[0705] 4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)aniline,

[0706]

[0707] 4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)-3-fluoroaniline,

[0708] 6-(4-cyclohexylphenoxy)pyridin-3-amine,

[0709]

[0710] 4-(4-(tert-butyl)phenoxy)aniline,

[0711]

[0712] 4-(4-isopropylphenoxy)aniline, and

[0713] 6-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)pyridin-3-amine.

[0714] In a particularly preferred embodiment, a method according to the second aspect of the present invention or a hydrochloride according to the fourth aspect of the present invention is provided, wherein the compound of formula (I) is 6-(4-(tert-butyl)phenoxy)pyridine-3-amine, i.e., the hydrochloride obtained by the method according to the second aspect of the present invention or the hydrochloride obtained by the fourth aspect of the present invention is 6-(4-(tert-butyl)phenoxy)pyridine-3-amine hydrochloride.

[0715] In another particularly preferred embodiment, a method according to the third aspect of the present invention or a monohydrochloride salt according to the fifth aspect of the present invention is provided, wherein the compound of formula (I) is 6-(4-(tert-butyl)phenoxy)pyridine-3-amine, that is, the monohydrochloride salt obtained by the method according to the third aspect of the present invention or the monohydrochloride salt of the fifth aspect of the present invention is 6-(4-(tert-butyl)phenoxy)pyridine-3-amine monohydrochloride.

[0716] In a particularly preferred embodiment, a hydrochloride salt of the fifth aspect of the invention is provided, wherein the hydrochloride salt is 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride and has a melting point of about 168°C to about 178°C, preferably about 171°C to about 175°C, and most preferably about 173°C (determined using differential scanning calorimetry (DSC)).

[0717] In another particularly preferred embodiment, a hydrochloride salt of the fifth aspect of the present invention is provided, wherein the hydrochloride salt is 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride, and has a CuKα radiation-determined Figure 3 X-ray powder diffraction pattern with 2θ values ​​shown in .

[0718] In a preferred embodiment, a hydrochloride salt according to the fifth aspect of the present invention is provided, wherein the hydrochloride salt is 6-(4-(tert-butyl)phenoxy)pyridine-3-amine monohydrochloride and has a purity of 100% (>=95% area, determined by HPLC-UV) after storage at 25°C, 60% rh for 24 months.

[0719] In another preferred embodiment, a hydrochloride according to the fifth aspect of the present invention is provided, wherein the hydrochloride is 6-(4-(tert-butyl)phenoxy)pyridine-3-amine monohydrochloride and has a purity of 98.9% (>=95% area, determined by HPLC-UV) after storage at 40°C, 75% rh for 6 months.

[0720] Use of the hydrochloride and monohydrochloride of the present invention

[0721] In a sixth aspect, the present invention provides the hydrochloride salt of the compound of formula (I) according to the fourth aspect of the present invention and the above embodiments thereof, preferably 6-(4-(tert-butyl)phenoxy)pyridin-3-amine hydrochloride, for use as a medicament.

[0722] In the seventh aspect, the present invention provides the monohydrochloride salt of the compound of formula (I) according to the fifth aspect of the present invention and the above-mentioned embodiments thereof, preferably 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride, for use as a drug.

[0723] In the eighth aspect, the present invention provides the hydrochloride salt of the compound of formula (I) according to the fourth aspect of the present invention and the above-mentioned embodiments thereof, preferably 6-(4-(tert-butyl)phenoxy)pyridine-3-amine hydrochloride, which is used in a method for treating and / or preventing cancer.

[0724] Also provided is the use of the hydrochloride of the compound of formula (I) and the above-mentioned embodiments thereof, preferably 6-(4-(tert-butyl)phenoxy)pyridine-3-amine hydrochloride, in the preparation of a medicament for treating and / or preventing cancer according to the fourth aspect of the present invention.

[0725] Also provided is the use of the hydrochloride of the compound of formula (I) and the above-mentioned embodiments thereof, preferably 6-(4-(tert-butyl)phenoxy)pyridin-3-amine hydrochloride, in the treatment and / or prevention of cancer according to the fourth aspect of the present invention.

[0726] In the ninth aspect, the present invention provides the monohydrochloride salt of the compound of formula (I) according to the fifth aspect of the present invention and its above-mentioned embodiment, preferably 6-(4-(tert-butyl)phenoxy)pyridine-3-amine monohydrochloride, which is used in a method for treating and / or preventing cancer.

[0727] Also provided is the monohydrochloride salt of the compound of formula (I) and the above-mentioned embodiments thereof, preferably the use of 6-(4-(tert-butyl)phenoxy)pyridine-3-amine monohydrochloride in the preparation of a drug for treating and / or preventing cancer in the fifth aspect of the present invention.

[0728] Also provided is the monohydrochloride salt of the compound of formula (I) and the above-mentioned embodiments thereof, preferably the use of 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride in the treatment and / or prevention of cancer according to the fifth aspect of the present invention.

[0729] In one embodiment of the fourth and fifth aspects of the present invention, the cancer is a Notch-dependent cancer, preferably a Notch-dependent cancer selected from T-cell acute lymphoblastic leukemia (T-ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), breast cancer, pancreatic cancer, prostate cancer, melanoma, brain tumors, tumor angiogenesis and colorectal cancer. Example

[0730] Hereinafter, the present invention will be described in more detail and particularly with reference to Examples, but these Examples are not intended to limit the present invention.

[0731] Material:

[0732] 4-(tert-butyl)-phenol (formula (IIIa)) and 2-chloro-5-nitro-pyridine (formula (IVa)) used in exemplary embodiments of the present invention are commercially available from a variety of sources, for example, from Sigma-Aldrich. In general, the structural units of formula (III) and (IV) are known and commercially available.

[0733] The compounds of formula (II) can be obtained according to the general method A.

[0734] Compounds of formula (I) can be obtained according to general method B.

[0735] The monohydrochloride salt of the compound of formula (I) described herein can be obtained according to General Procedure C.

[0736] instrument:

[0737] HPLC:

[0738] Device: Agilent 1100 series with DAD

[0739] Software: CDS Chromeleon 6.8

[0740] Column: Advanced Materials Technology Halo C18, 2.7μm, 100mm×4.6mm

[0741] Column temperature: 20℃

[0742] Mobile phase A: water

[0743] Mobile phase B: acetonitrile

[0744] gradient:

[0745] Flow rate: 1.2mL / min

[0746] Injection volume: 2.0 μL

[0747] Sample solvent: acetonitrile, for compounds of formula (Ia)

[0748] Acetonitrile / water 3:1 v / v, for the monohydrochloride of the compound of formula (Ia)

[0749] Sample concentration: 0.8 mg / mL

[0750] Autosampler temperature: 20°C

[0751] Detection: UV at 220nm

[0752] XRPD:

[0753] X-ray powder diffraction studies were performed using a Bruker D8 Advance, using a Cu anode at 40 kV, 40 mA. The software used for data acquisition was Diffrac.plus Part 11 version 3. No background correction or smoothing was performed on the patterns.

[0754] General Method A: Coupling

[0755] The compound of formula (III) (1 equivalent) and the compound of formula (IV) (1 equivalent) were dissolved in DMF or in DMSO (5 volumes) at room temperature (rt), followed by the addition of KCO (about 1.5 equivalents). The mixture was stirred at room temperature until one or preferably both of the compounds of formula (III) and (IV) were fully converted, after which ethyl acetate (8 volumes) and water (10 volumes) were added. The layers were separated, the organic layer was washed with aqueous NaHCO (4 volumes) and brine (4 volumes), and dried over anhydrous NaSO (0.5-1% wt / wt). The suspension was filtered, and the filter cake (NaSO) was washed with ethyl acetate (3 volumes).

[0756] Optional crystallization:

[0757] The combined filtrate is concentrated to about half its volume (i.e., about 6 volumes of ethyl acetate are distilled off). Subsequently, heptane (10 volumes) is added at Tout=50°C, and part of the solvent (about 10 volumes) is distilled off. The resulting concentrated solution is cooled to Tout=-20°C to obtain a suspension. The suspension is filtered, and the filter cake is washed with cold heptane (4 volumes) and dried on a rotary evaporator to obtain the corresponding nitro-diaryl compound of formula (II).

[0758] General Method B: Hydrogenation

[0759] In a high pressure reactor, the compound of formula (II) obtained according to general method A is dissolved in ethyl acetate (5 volumes). Then, a suspension of palladium activated carbon (preferably Pd-content 5% wt / wt; preferably about 1.25 mol% Pd) in ethyl acetate (1 volume) is added to the solution at room temperature through a funnel, and the funnel is rinsed with ethyl acetate (3 volumes). The high pressure reactor is purged with hydrogen, and the suspension is then stirred at room temperature under a hydrogen pressure of 0.5 bar until complete conversion. Thereafter, the suspension is filtered and the filter cake is rinsed with ethyl acetate (3 volumes).

[0760] Optional post-treatment including crystallization:

[0761] The filtrate is concentrated under reduced pressure to about half of its volume. Then, activated carbon is added at room temperature, and the resulting suspension is stirred at room temperature. Subsequently, the suspension is filtered, and the filter cake is washed with ethyl acetate (2×2 volumes). The combined filtrate is concentrated under reduced pressure to about 1 / 3 of the initial volume, and heptane (7 volumes) is added at Tout=40°C, and then about half of the solvent is distilled off. The concentrated solution is cooled to Tout=-20°C to obtain a suspension, which is further cooled to Tout=-24°C. Thereafter, the suspension is filtered, and the filter cake is washed with cold heptane (3 volumes), and dried on the filter overnight to obtain the corresponding amino-diaryl compound of formula (I).

[0762] General Method C: Salt Formation

[0763] The compound of formula (I) was dissolved in 2-propanol (4 volumes). The solution was heated to Tout = 40°C and at Tout = 40°C (Ti max =44.9 ° C) is added dropwise 5-6N HCl (about 1.0 equivalent) in 2-propanol. Optionally, seeds of the monohydrochloride salt of the compound of formula (I) (0.1% wt / wt) are then added. The (seeded) mixture is stirred at Ti = 40 ° C for about 0.5 hours to obtain a suspension. Heptane (4 volumes) is added at Ti = 40 ° C, and the suspension is further warmed to Ti = 45 ° C. A second portion of heptane (8 volumes) is added. The mixture is then warmed to Tout = 55 ° C and maintained at this temperature with stirring for about 1 hour.

[0764] Post-processing:

[0765] Over about 16 hours, the suspension is cooled to Ti = 13 ° C, then over about 30 minutes, further cooled to Ti = 0 ° C, and stirred at Ti = 0 ° C for 1 hour. The suspension is then filtered and the filter cake is washed with a 10: 1 mixture of heptane and 2-propanol (3 volumes). The filter cake is dried on a rotary evaporator (Tout = 50 ° C, <10 mbar) for 3 days to obtain a hydrochloride salt of the compound of formula (I), typically as a colorless crystalline solid.

[0766] Example 1A: 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (Formula (IIa))

[0767] According to General Method A: 4-(tert-butyl)-phenol (Formula (IIIa), 3.98 kg) and 2-chloro-5-nitro-pyridine (Formula (IVa), 4.13 kg) were dissolved in DMSO (21 L) at room temperature (rt), and K2CO3 (5.41 kg) was then added at room temperature over 17 minutes. The mixture was stirred at room temperature for 17.25 hours, after which ethyl acetate (33 L) and water (20 L) were added. The resulting biphasic mixture was stirred for 35 minutes and allowed to stand for an additional 35 minutes before the layers were separated. The organic layer was washed with NaHCO3 aqueous solution (8% wt / wt, 16.5 L) and brine (16.5 L) and dried over anhydrous Na2SO4 (2.5 kg). The suspension was filtered and the filter cake (Na2SO4) was washed with ethyl acetate (13 L). The combined filtrate was then concentrated under reduced pressure (25 L of ethyl acetate was distilled out). Heptane (mixture of isomers, 41 L) was then added at Tout = 50°C over 7 minutes, and 42 L of solvent was distilled off under reduced pressure. The resulting yellow solution was cooled to Tout = -20°C over 20 hours, and stirred at this temperature for 65 minutes to obtain a suspension. The suspension was filtered, and the filter cake was washed with cold heptane (mixture of isomers, 16.5 L), and dried overnight on a rotary evaporator to obtain 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (Formula (IIa), 6.2 kg, 87%) as a white solid.

[0768] Example 1B: 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (Formula (IIa))

[0769] According to General Method A: 4-(tert-butyl)-phenol (Formula (IIIa), 7.94 kg) and 2-chloro-5-nitro-pyridine (Formula (Va), 8.36 kg) were dissolved in DMSO (42 L) at room temperature (rt), and K2CO3 (10.96 kg) was then added at room temperature over 12 minutes. The mixture was stirred at room temperature for 21.5 hours, after which ethyl acetate (66 L) and water (42 L) were added. The resulting biphasic mixture was stirred for 68 minutes, allowed to stand for an additional 2 hours, and then the layers were separated. The organic layer was washed with aqueous NaHCO3 solution (8% wt / wt, 33 L) and brine (33 L), and dried over anhydrous Na2SO4 (5 kg). The suspension was filtered, and the filter cake (Na2SO4) was washed with ethyl acetate (25 L). The combined filtrate was then concentrated under reduced pressure (48 L of ethyl acetate was distilled off). Heptane (mixture of isomers, 84 L) was then added at Tout = 50°C over 67 minutes, and 79 L of solvent was distilled off under reduced pressure. The resulting yellow solution was cooled to Tout = -20°C over 20 hours and stirred at this temperature for 61 minutes to obtain a suspension. The suspension was filtered, and the filter cake was washed with cold heptane (mixture of isomers, 33 L) and dried overnight on a rotary evaporator to obtain 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (formula (IIa), in two portions, 4.96 and 5.06 kg, 70%) as a white solid. However, the material dissolved in 20 L of ethyl acetate combined with the mother liquor applied to the container according to the general method was transferred to the solvent changed from ethyl acetate to heptane to obtain a third portion of 3.59 kg (23%) as a white solid. The total yield in the first stage increased to 93%.

[0770] Example 2 (Comparative Example): 6-(4-(tert-butyl)phenoxy)pyridin-3-amine (Formula (Ia)) obtained by the method described in WO 2013 / 093885

[0771] 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (Formula (IIa), 8.6 g) and palladium activated carbon (2.35 g, 10% wt / wt palladium) in MeOH (86 mL) were stirred at room temperature in a H2-atmosphere (0.5 bar) for 2 hours to give 6-(4-(tert-butyl)phenoxy)pyridine-3-amine (Formula (Ia)). However, N-methylated byproducts were observed by HPLC, and the Pd content was detected to be 6.9 ppm by elemental analysis.

[0772] Example 3A: 6-(4-(tert-butyl)phenoxy)pyridin-3-amine (Formula (Ia))

[0773] According to General Method B: In a high pressure reactor, 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (Formula (IIa), 1.2 kg) was dissolved in ethyl acetate (6 L). A suspension of palladium activated carbon (119 g, 5% wt / wt palladium) in ethyl acetate (1.2 L) was then added to the solution at room temperature through a funnel, and the funnel was rinsed with ethyl acetate (3.6 L). The high pressure reactor was purged with hydrogen (5 bar), and the suspension was then stirred at room temperature (832 rpm) under a hydrogen pressure of 0.5 bar until complete conversion (2 hours 20 minutes). Thereafter, the suspension was filtered, and the filter cake was rinsed with ethyl acetate (3.6 L).

[0774] Work-up: In this case, the products of 5 hydrogenation runs were combined and worked up according to the general method:

[0775] The filtrates (from 5 runs) were combined and concentrated under reduced pressure (74 L of ethyl acetate was distilled off). Activated carbon (605 g) was then added at Tout = 25°C, and the resulting suspension was stirred at Tout = 25°C for 1 hour and 10 minutes. The suspension was then filtered and the filter cake was washed with ethyl acetate (2×12 L). The combined filtrates were concentrated under reduced pressure (42 L of ethyl acetate was distilled off), and heptane (mixture of isomers, 42 L) was added at Tout = 40°C over 12 minutes, and then 36 L of solvent was distilled off under reduced pressure. The concentrated solution was cooled to Tout = -20°C over 6 hours to obtain a suspension, which was further stirred at Tout = -24°C for 1 hour. Thereafter, the suspension was filtered, and the filter cake was washed with cold heptane (mixture of isomers, 19 L), and dried with a filter overnight to obtain 6-(4-(tert-butyl)phenoxy)pyridine-3-amine (Formula (Ia), 4.95 kg, 91%) as a light red solid.

[0776] Example 3B: 6-(4-(tert-butyl)phenoxy)pyridin-3-amine (Formula (Ia))

[0777] According to General Method B: In a high pressure reactor, 2-(4-(tert-butyl)phenoxy)-5-nitropyridine (Formula (IIa), 50 g) was dissolved in 2-propanol (0.4 L). A suspension of palladium activated carbon (5 g, 5% wt / wt palladium) in 2-propanol (25 mL) was then added to the solution through a funnel at room temperature, and the funnel was rinsed with 2-propanol (25 mL). The high pressure reactor was purged with hydrogen (5 bar), and the suspension was then stirred (832 rpm) at room temperature under a hydrogen pressure of 0.1 bar until complete conversion (7 hours 30 minutes). Thereafter, the suspension was filtered, and the filter cake was rinsed with 2-propanol (0.2 L).

[0778] Work-up: the filtrate was concentrated under reduced pressure (0.65 L of 2-propanol was distilled off) and 6-(4-(tert-butyl)phenoxy)pyridin-3-amine was isolated as a solid.

[0779] Example 4: 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride

[0780] According to General Method C: 6-(4-(tert-butyl)phenoxy)pyridin-3-amine (Formula (Ia), 4.95 kg) was dissolved in 2-propanol (20 L). The solution was heated to Tout = 40 °C and heated at Tout = 40 °C (Ti) for 20 minutes. max =44.9 ° C) was added dropwise with 5-6N HCl (3.7 L, 1.01 equiv.) in 2-propanol. 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride seeds (5 g) were added and the seeded mixture was stirred at Ti = 40 ° C for 0.5 hours to obtain a suspension. Heptane (mixture of isomers, 20 L) was added at Ti = 40 ° C over 33 minutes and the suspension was further warmed to Ti = 45 ° C. A second portion of heptane (mixture of isomers, 40 L) was added dropwise over 54 minutes. The mixture was then warmed to Tout = 55 ° C and kept stirring at this temperature for 1 hour.

[0781] Post-processing:

[0782] The suspension was cooled to Ti = 13 ° C. over 16 hours, then further cooled to Ti = 0 ° C. over 30 minutes, and stirred at Ti = 0 ° C. for 1 hour. The suspension was then filtered and the filter cake was washed with a mixture of 10:1 heptane (isomer mixture) and 2-propanol (2×16.5 L). The filter cake was dried on a rotary evaporator (Tout = 50 ° C., <10 mbar) for 3 days to give the title compound as a colorless crystalline solid (5.02 kg, 88%).

[0783] Example 5: Salt formation with 6-(4-(tert-butyl)phenoxy)pyridin-3-amine

[0784] Different salt formations were tested according to the method shown in Table 1 below:

[0785] Table 1: Salt formation with 6-(4-(tert-butyl)phenoxy)pyridin-3-amine

[0786]

[0787]

[0788] Example 6: Forced degradation of 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride

[0789] instrument:

[0790] Light Stabilization Chamber: Solarbox 1500e

[0791] Oven: Salvis vacuum drying oven VC-20

[0792] Heating unit: lkamag RET-GS with lka ETSSD and stainless steel heating block

[0793] Vials: Supelco V-bottles and screw caps with PTFE septa

[0794] Gas-tight vials: Agilent 10mL HS-GC clear glass vials and crimp caps with non-PTFE septa

[0795] Quartz glass cuvette: Hellma precision cuvette Suprasil model 117.100-QS, path length 10 mm, screw cap with silicone septum

[0796] HPLC: As above

[0797] Analytical methods:

[0798] Prior to the forced degradation test, the above-mentioned HPLC test method was used to determine the content and purity of 6-(4-(tert-butyl)phenoxy)pyridine-3-amine monohydrochloride and the area % content of each impurity and degradation product in the 6-(4-(tert-butyl)phenoxy)pyridine-3-amine monohydrochloride sample obtained from the degradation test.

[0799] The identity of 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride was determined by comparison with the retention time of the reference compound.

[0800] The content and purity of 6-(4-(tert-butyl)phenoxy)pyridine-3-amine monohydrochloride were determined by HPLC with UV detection at 220 nm using area normalization for purity determination and external standard calibration for content determination. In all experiments, UV spectra from 200 nm to 950 nm were recorded and the peak purity of 6-(4-(tert-butyl)phenoxy)pyridine-3-amine monohydrochloride was also evaluated.

[0801] Only a single determination was made for each test condition.

[0802] For each test condition described below, one sample was prepared and analyzed according to the HPLC method.

[0803] 1. Solid state with heat stress

[0804] Approximately 20.4 mg and 50.1 mg of 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride were weighed into Supelco Type V vials. The vials were closed with screw caps and stored in a heating block of a heating unit operated at 100° C.±5° C. for 20 hours (20 mg sample) and 68 hours (50 mg sample), respectively.

[0805] After storing the expected time at 100 ℃, each sample is cooled to room temperature, and the content in the bottle is dissolved in the sample solvent (acetonitrile / water 3:1v / v) of about 4mL. The solution obtained is quantitatively transferred to a 25mL volumetric flask (20mg sample) or a 50mL volumetric flask (50mg sample) respectively. The bottle is then rinsed 3 times with about 4mL sample solvent, and the content of the bottle is also transferred to a 25mL volumetric flask subsequently each time. After filling the sample solvent to a certain volume and fully shaking in a flask, the aliquot of the solution is transferred to the HPLC bottle for analysis.

[0806] Results: 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride is stable in a solid state at 100°C. No significant changes in purity and purity characteristics were observed after storage at 100°C for 68 hours. The observed decrease in content was within the acceptable variation of the method (±2%).

[0807] 2. Solid-state by UV / VIS radiation stress

[0808] Two samples of 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride, 20.23 mg and 20.17 mg respectively, were weighed into quartz glass cuvettes. Both cuvettes were closed with screw caps. One of the cuvettes was protected by wrapping it in aluminum foil. This sample served as a dark control. The two cuvettes were placed side by side in a photostability chamber and then exposed to an applied 500 W / m 2 Energy UV / VIS radiation until a total illuminance of 1200kLux·h is reached.

[0809] After exposure to UV / VIS radiation at 1200kLux·h illumination, the sample is placed at room temperature, and the contents of the cuvette are dissolved in about 2mL of sample solvent (acetonitrile / water 3:1 v / v). The resulting solution is quantitatively transferred to a 25mL volumetric flask. The cuvette is then rinsed 5 times with about 2mL of sample solvent, and the contents of the cuvette are subsequently also transferred to a 25mL volumetric flask each time. After filling the sample solvent to a certain volume in the flask and fully shaking, an aliquot of the solution is transferred to an HPLC vial for analysis.

[0810] Results: In the solid state, 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride is stable to UV / VIS radiation. 2After 1200 kLux·h illumination with an energy of 100 kLux·h, the purity dropped by 0.6 area%, which is mainly related to the appearance of two unknown impurities. The observed 2.1% w / w content drop is not related to UV / VIS radiation, because the content of the dark control has a similar value (drop of 2.4% w / w).

[0811] 3. Alkali and heat stress in aqueous solution

[0812] About 20 mg of (4×)6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride was weighed into a 10 mL GC-HS vial, and 2.0 mL of 0.1 M NaOH aqueous solution was added. 4 vials were packed and shaken. 2 vials were stored in an oven operated at 60°C ± 5°C, and 2 vials were stored in an oven operated at 90°C ± 5°C. In addition, a blank sample was prepared by transferring a 2.0 mL volume of 0.1 M NaOH aqueous solution to a 10 mL GC-HS vial. After packing, the vial containing the blank was stored in an oven operated at 90°C ± 5°C. The test conditions are summarized in Table 2:

[0813] Table 2: Test conditions for alkali and heat stress in aqueous solution

[0814]

[0815]

[0816] After storing the expected time under the conditions of definition, each sample is cooled to room temperature.Then, by adding 2.0mL of 0.1M HCl aqueous solution and sample.For each sample, the bottle content is quantitatively transferred to a 25mL volumetric flask.Then the bottle is rinsed 3 times with about 5mL sample solvent (acetonitrile / water 3:1v / v), and the content of the bottle is also transferred to a 25mL volumetric flask at each time.After filling the sample solvent to a certain volume and fully shaking in a flask, the aliquot of the solution is transferred to the HPLC bottle for analysis.

[0817] All recorded chromatograms were identified, assayed, and evaluated for purity according to the analytical method [1]. In addition, peak purity was evaluated in the chromatograms of the stability samples. For each analytical sequence, SST was performed as specified in the analytical method [1]. All SST criteria were met for each analytical sequence.

[0818] Example 7: Solubility of 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride and 6-(4-(tert-butyl)phenoxy)pyridin-3-amine

[0819] The solubility of 6-(4-(tert-butyl)phenoxy)pyridin-3-amine (Formula (Ia)) and its monohydrochloride, i.e., 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride, in water was evaluated at different pH values ​​according to Tables 3 and 4. The solubility of 6-(4-(tert-butyl)phenoxy)pyridin-3-amine (Formula (Ia)) in water according to Table 3 was determined as follows: 500 mg of the free base was added to 14 mL of an acidic medium at pH = 2, 4, a neutral medium at pH = 7, and an alkaline medium at pH = 10 to obtain a suspension in a calculated concentration range of about 35 mg / mL. The solubility of 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride in water according to Table 4 was determined as follows: 100 mg of the HCl salt was added to an acidic medium at pH = 2 and 4 and a neutral medium at pH = 7, respectively, to obtain a solution. The most important observation was that in a neutral solution at pH = 7, the pH was lowered to pH = 1 by adding 100 mg of HCl salt.

[0820] The solubility of 6-(4-(tert-butyl)phenoxy)pyridin-3-amine (Formula (Ia)) in water was found to be very poor, regardless of pH. The solubility limit of the compound of Formula (Ia) in 0.01% HCl was determined to be 100 mg in 190 mL (0.53 mg / mL). In contrast, the monohydrochloride salt of the compound of Formula (Ia) was found to be very soluble in water.

[0821] Table 3: Solubility of 6-(4-(tert-butyl)phenoxy)pyridin-3-amine at different pH values

[0822]

[0823] Table 4: Solubility of 6-(4-(tert-butyl)phenoxy)pyridin-3-amine HCl salt at different pH values

[0824]

[0825]

[0826] Example 8: Stability Study of 6-(4-(tert-butyl)phenoxy)pyridine-3-amine Monohydrochloride:

[0827] Two different types of stability studies were conducted for 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride, including short-term and long-term stability studies at 25°C (RH, 60%), -5°C and -20°C for up to 36 months, respectively, and an accelerated study at 40°C (RH, 75%) for 6 months. The results of these studies are shown in Tables 7-14 below. In terms of analytical determinations, six tests were involved, including appearance, free base content mean and purity mean, water, IR and XRPD. Appearance was determined by visual inspection. The product should be a white or off-white powder. According to USP <921> Coulometric determination of water content. According to USP <197> , 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride was identified by IR spectroscopy and comparison of the obtained spectrum with a reference standard. According to USP <941> X-ray powder diffraction (XRPD) was performed with reference to the XRPD spectrum. The purity and content determination of the free alkali were performed by HPLC-UV. Two methods were used. The mobile phase in the first method was water and acetonitrile. The mobile phase in the second method was water (0.5 mL of trifluoroacetic acid was added to 1000 mL of water) and acetonitrile (0.4 mL of trifluoroacetic acid was added to 1000 mL of acetonitrile). The equipment and chromatographic conditions for the purity and content of 6-(4-(tert-butyl)phenoxy)pyridine-3-amine monohydrochloride identified and determined by HPLC-UV according to the first method and the second method are shown in Table 5 and Table 6, respectively.

[0828] Table 5: Equipment and chromatographic conditions for the identification and determination of the purity and content of 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride by HPLC-UV according to the first method

[0829]

[0830]

[0831] Table 6: Equipment and chromatographic conditions for the identification and determination of the purity and content of 6-(4-(tert-butyl)phenoxy)pyridin-3-amine monohydrochloride by HPLC-UV according to the second method

[0832]

[0833]

[0834] Table 7: 6 month stability study using the following storage conditions: 25°C, 60% rh

[0835]

[0836] Table 8: 36 month stability study using the following storage conditions: 25°C, 60% rh

[0837]

[0838]

[0839] Table 9: 6 month stability study using the following storage conditions: 5°C

[0840] Freeing Data 3 months 6 months Acceptance Criteria result result result White to off-white powder White powder White powder White powder 80.9-92.9% m / m (anhydrous, solvent-free) 89.4 87.2 87.6 >=95% area 100.0 99 99 Report results [% m / m] 0.01 0.02 0.02 Comply with reference conform to conform to conform to Comply with reference According to the diffraction pattern Not tested Not tested

[0841] Table 10: 36 month stability study using the following storage conditions: 5°C

[0842]

[0843] Table 11: 6 month stability study using the following storage conditions: -20°C

[0844] Freeing Data 3 months 6 months Acceptance Criteria result result result White to off-white powder White powder White powder White powder 80.9-92.9% m / m (anhydrous, solvent-free) 89.4 86.1 87.3 >=95% area 100 99 99 Report results [% m / m] 0.01 0.02 0.02 Comply with reference conform to conform to conform to Comply with reference According to the diffraction pattern Not tested Not tested

[0845] Table 12: 36 month stability study using the following storage conditions: -20°C

[0846]

[0847] Table 13: 6 month stability study using the following storage conditions: 40°C, 75% rh

[0848] Freeing Data 3 months 6 months Acceptance Criteria result result result White to off-white powder White powder White powder White powder 80.9-92.9% m / m (anhydrous, solvent-free) 87.0 89.2 87.4 >=95% area 99.2 99.6 98.9 Report results [% m / m] 0.02 0.01 0.02 Comply with reference conform to conform to conform to Comply with reference According to the diffraction pattern Not tested conform to

[0849] Table 14: Overview of stability studies performed

[0850]

[0851]

Claims

1. A method for preparing a hydrochloride salt of a compound of formula (Ia), The Method include: Reducing the compound of formula (IIa) with hydrogen in the presence of a palladium catalyst and a solvent, wherein the solvent is a polar aprotic solvent or a C3-C10 alcohol, To form the compound of formula (Ia), The method further comprises reacting the compound of formula (Ia) with less than about 1.5 molar equivalents of hydrochloric acid to form a monohydrochloride salt of the compound of formula (Ia).

2. The process according to claim 1, wherein the palladium catalyst is present in an amount less than 7 mol%.

3. The method according to claim 1 or 2, wherein the solvent is selected from the group consisting of 2-propanol, acetone, 2-butanone, 3-methyl-2-butanone, cyclohexanone, acetonitrile, chlorobenzene, dichloromethane, chloroform, trichloroethane, ethylene chloride, benzaldehyde, sulfolane, ethyl acetate, propyl acetate, amyl acetate, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide, diethyl carbonate, propylene carbonate, ethylene carbonate, methyl ethyl ketone, methyl isopropyl ketone, methyl isobutyl ketone, and mixtures thereof.

4. The process according to any one of claims 1 to 3, wherein the solvent is ethyl acetate.

5. The method according to any one of claims 1 to 4, further comprising crystallizing the monohydrochloride salt.

6. The monohydrochloride salt of the compound of formula (Ia), 7. A hydrochloride according to claim 6, Features It has a melting point of 173°C.

8. A pharmaceutical preparation comprising a hydrochloride according to claim 6 or 7.

9. A hydrochloride according to claim 6 or 7 or a pharmaceutical preparation according to claim 8 for use as a medicament.

10. A hydrochloride according to claim 6 or 7 or a pharmaceutical preparation according to claim 8 for use in a method for the treatment and / or prevention of cancer.